- P Wave Amplitude [CMO:0000263] — The magnitude of the P wave, the initial deflection of the cardiac cycle representing excitation of the atria as presented in an electrocardiogram.
- P Wave Duration [CMO:0000264] — The time from start to finish of the P wave , in the electrocardiograph illustrating the initial deflection of the cardiac cycle, representing the excitation of the atria.
- Pancreas Dry Weight [CMO:0000627] — The weight of the pancreas after desiccation. The pancreas is the compound endocrine/exocrine gland located behind the stomach in vertebrates which secretes hormones (insulin, glucagon, and somatostatin) into the bloodstream and digestive enzymes and ions such as sodium bicarbonate into the small intestine.
- Pancreas Hormone Composition Measurement [CMO:0002586] — Any measurement involving the composition, that is, the absolute amount, relative amount or type of one or more hormones in a sample of tissue from the pancreas.
- Pancreas Insulin Level [CMO:0002587] — Measurement of the amount of insulin in a sample of tissue from the pancreas without division or fractionation of the tissue (for example separation of the endocrine and exocrine pancreas). Insulin is the fuel-regulating peptide hormone which is formed from proinsulin in the beta cells of the pancreatic islets and which promotes the storage of glucose and the uptake of amino acids, increases protein and lipid synthesis, and inhibits lipolysis and gluconeogenesis.
- Pancreas Insulin Level to Pancreas Total Protein Ratio [CMO:0001144] — The ratio of the amount of insulin, the polypeptide hormone secreted by the islets of Langerhans which helps regulate the metabolism of carbohydrates and fats, in the pancreas to the total amount of protein in the pancreas without division or fractionation of the tissue (for example separation of the endocrine and exocrine pancreas).
- Pancreas Lesion Measurement [CMO:0001150] — Measurement of a lesion in the pancreas, the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally. A lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined.
- Pancreas Measurement [CMO:0001049] — Any measurement, morphological or physiological, involving the pancreas or any part thereof. The pancreas is the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally.
- Pancreas Molecular Composition Measurement [CMO:0002576] — Any quantitation of the molecules, atoms and/or ions which constitute the chemical make-up of a sample of pancreatic tissue.
- Pancreas Morphological Measurement [CMO:0000332] — Measurement of the physical form or structure of the pancreas, the compound endocrine/exocrine gland located behind the stomach in vertebrates which secretes hormones (insulin, glucagon, and somatostatin) into the bloodstream and digestive enzymes and ions such as sodium bicarbonate into the small intestine.
- Pancreas Non-tumorous Lesion Measurement [CMO:0001151] — Measurement of a pancreas lesion which is not neoplastic in origin. A lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined. Examples of non-tumorous lesions would include wounds, sores, ulcers, infarctions, etc.
- Pancreas Peptide Hormone Composition Measurement [CMO:0002585] — Any measurement involving the composition, that is, the absolute amount, relative amount or type of one or more peptide hormones in a sample of tissue from the pancreas.
- Pancreas Protein/peptide Composition Measurement [CMO:0002580] — Any measurement involving the composition, that is, the absolute amount, relative amount or type of one or more proteins or peptides in any sample of pancreas tissue.
- Pancreas Ribonucleic Acid Composition Measurement [CMO:0003266] —
- Pancreas Total Protein Level [CMO:0001142] — Measurement of the amount of total protein in the pancreas, the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally, or in a specified sample of pancreas tissue without division or fractionation of the tissue (for example separation of the endocrine and exocrine pancreas).
- Pancreas Tumorous Lesion Measurement [CMO:0001152] — Measurement of a pancreas lesion which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Pancreas Weight [CMO:0000333] — The weight of the pancreas, the compound endocrine/exocrine gland located behind the stomach in vertebrates which secretes hormones (insulin, glucagon, and somatostatin) into the bloodstream and digestive enzymes and ions such as sodium bicarbonate into the small intestine.
- Pancreas Weight as A Percentage of Body Weight [CMO:0000629] —
- Pancreas Weight to Body Weight Ratio [CMO:0000630] —
- Pancreas Weight to Tibia Length [CMO:0002996] —
- Pancreas Wet Weight [CMO:0000626] — The weight of the pancreas after removal from the body but without desiccation. The pancreas is the compound endocrine/exocrine gland located behind the stomach in vertebrates which secretes hormones (insulin, glucagon, and somatostatin) into the bloodstream and digestive enzymes and ions such as sodium bicarbonate into the small intestine.
- Pancreatic Beta Cell Count [CMO:0000319] — The number of islet cells which secrete insulin and make up the islets of Langerhans in the pancreas in a specified sample size.
- Pancreatic Insulitis Measurement [CMO:0002297] — Any measurement of insulitis of the pancreas, that is, lymphocytic infiltration of the islets of Langerhans, suggesting an inflammatory or immunologic reaction.
- Pancreatic Islet Area [CMO:0001054] — A measurement of the extent of a two-dimensional surface of or plane through a single pancreatic islet, or a measurement of the total area occupied by pancreatic islets in a cross-section of the pancreas. The pancreatic islets are the irregular microscopic structures scattered throughout the pancreas and comprising its endocrine portion.
- Pancreatic Islet Area to Total Pancreatic Area Ratio [CMO:0001058] — A calculated value in which the area of a cross-section of the pancreas which is occupied by pancreatic islets is divided by the total area of the pancreas cross-section, and the result presented as a ratio, fraction, quotient or percentage thus normalizing it to the size of the pancreas.
- Pancreatic Islet Beta Cell Area [CMO:0001060] — The area of, that is, the extent of a two-dimensional surface of or plane through, the beta cells in a pancreatic islet. A beta cell is a type of basophilic cell that makes up most of the bulk of the pancreatic islets (i.e. the islets of Langerhans) and secretes insulin.
- Pancreatic Islet Damage Composite Score [CMO:0001156] — A measurement of the extent of pancreatic islet damage (e.g. fibrosis) which is derived from a combination of multiple measurements and/or objective or subjective severity scores according to a specified formula or set of criteria.
- Pancreatic Islet Insulin Level [CMO:0001857] — The amount of insulin in a specified sample of pancreatic islet tissue, i.e. one or more of the islets of Langerhans, the small, encapsulated, irregular, microscopic structures scattered throughout the pancreas and comprising its endocrine portion. The pancreas is the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally. Insulin is the fuel-regulating peptide hormone which is formed from proinsulin in the beta cells of the pancreatic islets and which promotes the storage of glucose and the uptake of amino acids, increases protein and lipid synthesis, and inhibits lipolysis and gluconeogenesis.
- Pancreatic Islet Insulin Output [CMO:0003783] — A calculated measure of the amount of insulin secretion from a single pancreatic islet per unit of time.
- Pancreatic Islet Insulin Release Measurement [CMO:0001216] — Any measurement pertaining to the secretion of insulin, the major fuel-regulating peptide hormone formed from proinsulin in the beta cells of the pancreatic islets of Langerhans, from the pancreatic islets.
- Pancreatic Islet Lesion Measurement [CMO:0001153] — Measurement of a lesion involving one or more pancreatic islets, i.e. islets of Langerhans, the endocrine, hormone-producing portion of the pancreas. A lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined.
- Pancreatic Islet Measurement [CMO:0001050] — Any measurement, morphological or physiological, involving one or more pancreatic islets, i.e. islets of Langerhans, the endocrine, hormone-producing portion of the pancreas.
- Pancreatic Islet Molecular Composition Measurement [CMO:0001856] — Any quantification of the amounts or proportions of proteins, lipids, minerals, nutrients, gases, or other substances in a specified sample of pancreatic islet tissue, i.e. one or more of the islets of Langerhans, the small, encapsulated, irregular, microscopic structures scattered throughout the pancreas and comprising its endocrine portion. The pancreas is the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally.
- Pancreatic Islet Morphological Measurement [CMO:0001052] — Measurement of the physical form or structure of one or more pancreatic islets, i.e. islets of Langerhans, the endocrine, hormone-producing portion of the pancreas.
- Pancreatic Islet Non-tumorous Lesion Count [CMO:0001157] — The number of pancreatic islets which display lesions in a particular sample.
- Pancreatic Islet Non-tumorous Lesion Measurement [CMO:0001154] — Measurement of a pancreatic islet lesion which is not neoplastic in origin. A lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined. Examples of non-tumorous lesions would include wounds, sores, ulcers, infarctions, etc.
- Pancreatic Islet Physiological Measurement [CMO:0001215] — Any measurement relating to the function of the pancreatic islets or their cells. Pancreatic islets, i.e. islets of Langerhans, are the endocrine, hormone-producing portion of the pancreas.
- Pancreatic Islet Protein/peptide Composition Measurement [CMO:0002582] — Any measurement involving the composition, that is, the absolute amount, relative amount or type of one or more proteins or peptides in a specified sample of tissue derived from one or more pancreatic islets.
- Pancreatic Islet Tumorous Lesion Measurement [CMO:0001155] — Measurement of a pancreatic islet lesion which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Pancreatic Islet Weight [CMO:0001815] — Measurement of the weight, i.e., the heaviness or the force with which an object is drawn toward the earth by gravity, of a single pancreatic islet or of the total of all of the islets in the entire pancreas or in a specified part thereof. The pancreas is the elongated, racemose gland containing both endocrine and exocrine elements which secretes hormones such as insulin and glucagon internally and digestive enzymes externally. A pancreatic islet is a small encapsulated region of the pancreas containing endocrine (i.e., hormone-producing) cells.
- Parasite Count [CMO:0001827] — The enumeration, i.e. measurement of the total number, of individual parasitic organisms in a specified sample of an infected tissue or bodily fluid, or in the entire body of the host. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host.
- Parasite Egg/oocyst Count [CMO:0002543] — The enumeration, i.e. measurement of the total number, of individual, parasitic organisms in the initial stage of developement found in a specified sample of an infected tissue or bodily fluid, or in the entire body of the host. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host. The egg or oocyst stage usually precedes a larval stage of parasite development.
- Parasite Length [CMO:0002509] — The distance between the two ends, that is, the extent of the longest dimension, of an individual parasitic organism in a specified sample of an infected tissue or bodily fluid from the host organism. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host.
- Parasite Size Measurement [CMO:0002508] — Any measurement of the physical dimensions, proportions, magnitude, or extent of individual parasitic organisms in a specified sample of an infected tissue or bodily fluid, or in the entire body of the host. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host.
- Parasitic Infection Incidence/prevalence Measurement [CMO:0002026] — Any measurement in which the number of individuals in a study population that display a specified parasitic infection at a point in time or develop a specified parasitic infection within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A parasitic infection is invasion and multiplication of parasites in body tissues, especially that causing local cellular injury due to competitive metabolism, toxins, intracellular replication, or antigen-antibody response. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host.
- Parasitic Infection Population Measurement [CMO:0003585] — This is any measurement which deals with parasitic infections in terms of population, geography or demographics.
- Parasitic Infection Severity Measurement [CMO:0001826] — This is any measurement of the degree to which infection by or the presence of a parasite has caused pain or damage, or of the degree to which a parasite has established lesions or infectious colonies, and/or taken over or interfered with the normal functioning of the body as a whole, or of one or more organs, tissues, cells or subcellular mechanisms of an organism. A parasitic infection is the invasion and colonization of one or more tissues in the body by a parasite, an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host.
- Parietal Lobe Ribonucleic Acid Composition Measurement [CMO:0003305] —
- Parotid Gland Ribonucleic Acid Composition Measurement [CMO:0003320] —
- Partial Pressure of Blood Carbon Dioxide (Pco2) [CMO:0000283] — The force per unit area attributable to the carbon dioxide, a colorless, odorless, incombustible gas formed during respiration and composed of one atom of carbon and two atoms of oxygen, dissolved in a specified volume of blood, defined as the force per unit area exerted by carbon dioxide in a mixture of gases in equilibrium with such a sample of blood at the same temperature.
- Partial Pressure of Blood Oxygen [CMO:0000381] — The force per unit area attributable to the oxygen, the chemical element with atomic number 8 which is the essential agent in the respiration of plants and animals, dissolved in a specified volume of blood.
- Partial Pressure of Brain Gray Matter Oxygen [CMO:0003627] — The quantification of interstitial oxygen in the gray matter of the brain, the portion of the central nervous system enclosed within the cranium which is composed of gray matter and white matter and is the primary center for the regulation and control of bodily activities.The brain tissue partial pressure of oxygen (PtO2) depends on the cerebral metabolic rate (CMR), the local cerebral blood flow (CBF) and the systemic exposure of hypoxia.
- Partial Pressure of Brain White Matter Oxygen [CMO:0003626] — The quantification of interstitial oxygen in the white matter of the brain, the portion of the central nervous system enclosed within the cranium which is composed of gray matter and white matter and is the primary center for the regulation and control of bodily activities.The brain tissue partial pressure of oxygen (PtO2) depends on the cerebral metabolic rate (CMR), the local cerebral blood flow (CBF) and the systemic exposure of hypoxia.
- Partial Pressure of Pancreatic Islet Oxygen [CMO:0001219] — A measurement of the partial pressure of oxygen measured directly within the pancreatic islet. The partial pressure of oxygen is the pressure exerted by oxygen dissolved in the islet milieu and is proportional to the concentration of oxygen in the liquid.
- Patent Ductus Arteriosus Score [CMO:0002566] — A measurement of the existance and severity of a patent ductus arteriosus (PDA) when such a measurement is derived from a combination of multiple measurements and/or an objective or subjective ranking or rating system according to a specified formula or set of criteria. PDA is the abnormal persistence of an open lumen in the ductus arteriosus, between the aorta and the pulmonary artery, after birth.
- Peak Aortic Velocity [CMO:0001481] — The maximum speed at which the blood flows through the aorta during the cardiac cycle, expressed as distance per unit of time.
- Peak Carotid Artery Blood Flow Velocity [CMO:0003814] — Measurement of peak carotid artery blood flow velocity, the top speed (systolic) with which blood moves along the circulation in any particular segment of carotid artery. Blood flow velocity is related directly to blood flow and inversely to cross-sectional area. Blood flow velocity can be measured indirectly by Doppler ultrasound
- Penis Ribonucleic Acid Composition Measurement [CMO:0003321] —
- Percent Change in Antibody Titer [CMO:0002550] — A calculated measurement of the relative difference in antibody titer between a treated state and a control state or between two points in time, expressed as a percentage.
- Percent Change in Arterial Blood Flow Rate [CMO:0000749] —
- Percent Change in Developed Blood Pressure [CMO:0000745] — A calculated measurement of the difference in developed blood pressure between a treated state and a control state, expressed as a percentage. Developed pressure is systolic minus diastolic pressure when measured in an isolated organ or vessel under conditions where perfusion pressure or flow can be controlled.
- Percent Change in Diastolic Blood Pressure [CMO:0001017] — The relative difference in the diastolic blood pressure between two points or two conditions, expressed as a percentage. The diastolic pressure is the minimum arterial pressure within the cardiac cycle, usually at the point at which the heart is in a state of relaxation and expansion. This is the time when the ventricles fill with blood.
- Percent Change in Food Intake [CMO:0001778] — A calculated measurement of the relative difference in the amount of food (material, usually of plant or animal origin, that contains essential nutrients such as carbohydrates, fats, proteins, vitamins, and/or minerals and that is ingested and assimilated by an organism to produce energy, stimulate growth, and maintain life) taken in for utilization by the body, between a treated state and a control state or between two points in time, expressed as a percentage.
- Percent Change in Food Intake Volume [CMO:0001779] — A calculated measurement of the relative difference in the volume, i.e., the size of the three dimensional space occupied by the food (material, usually of plant or animal origin, that contains essential nutrients such as carbohydrates, fats, proteins, vitamins, and/or minerals and that is ingested and assimilated by an organism to produce energy, stimulate growth, and maintain life) taken in for utilization by the body, between a treated state and a control state or between two points in time, expressed as a percentage.
- Percent Change in Food Intake Weight [CMO:0001780] — A calculated measurement of the relative difference in the weight of food (material, usually of plant or animal origin, that contains essential nutrients such as carbohydrates, fats, proteins, vitamins, and/or minerals and that is ingested and assimilated by an organism to produce energy, stimulate growth, and maintain life) taken in for utilization by the body, between a treated state and a control state or between two points in time, expressed as a percentage. Weight is the vertical force experienced by a mass as a result of gravitation.
- Percent Change in Heart Rate [CMO:0000742] —
- Percent Change in Hematocrit [CMO:0002539] — A calculated measurement of the relative difference in hematocrit (the percentage of total blood volume that is made up of red blood cells) between a treated state and a control state or between two points in time, expressed as a percentage.
- Percent Change in Left Ventricular Developed Pressure [CMO:0000751] — A calculated measurement of the difference in developed pressure measured in the heart left ventricle between a treated state and a control state, expressed as a percentage. Developed pressure is systolic minus diastolic pressure when measured in an isolated organ or vessel under conditions where perfusion pressure or flow can be controlled.
- Percent Change in Left Ventricular Systolic Blood Pressure [CMO:0000754] — The relative difference in the pressure within the heart left ventricle at the point of maximal contraction, when the blood is forced from the left ventricle into the aorta, between two points in time or two conditions expressed as a percentage.
- Percent Change in Mean Arterial Blood Pressure [CMO:0002035] — The difference in mean arterial blood pressure between two points in time or two conditions expressed as a percentage (the proportion or rate per hundred parts).
- Percent Change in Pulse Pressure [CMO:0002723] — A calculated measurement of the relative difference in pulse pressure between a treated state and a control state or between two points in time, expressed as a percentage.
- Percent Change in Respiration Rate [CMO:0000531] — Difference in respiratory rate between two points in time or two conditions expressed as a percentage.
- Percent Change in Systolic Blood Pressure [CMO:0000747] — The relative difference in the maximum arterial blood pressure, that is the pressure at the point of maximal contraction of the heart, between two points in time or two conditions expressed as a percentage.
- Percent Change in Tidal Volume [CMO:0000532] — Difference in tidal volume between two points in time or two conditions expressed as a percentage.
- Percent Change in Ventilation [CMO:0000288] — Change in the amount of air breathed in and out between two points in time or two conditions expressed as a percentage.
- Percent of Live Offspring Per Litter [CMO:0000643] — The quantity determined by count of the number of animals in a group of neonates, products of one gestation produced at one birth by a multiparous mammal, that survive and are alive at birth, divided by the total number of offspring in the litter, expressed as a percent.
- Percent of Time Spent in Voluntary Immobility [CMO:0001044] — Calculated measurement of the relative amount of experiment time that an organism or experimental subject spends frozen, that is, not moving from one place or position to another, when such behavior originated with or was undertaken, controlled, or accomplished as a result of that organism's free will or choice, expressed as a percentage.
- Percent Protection By Treatment for Schistosoma Mansoni [CMO:0003569] — A measurement of the degree to which the presentation of the Schistosomiasis disease state, i.e. infection with trematode worms of Schistosomiasis mansoni), has been reduced in a population as a result of some intervening treatment.
- Percentage of 13 Cm2 Floor Sectors Crossed Into, out of or Within A Discrete Space in An Experimental Apparatus [CMO:0003788] — The percentage of equilateral right-angled grid elements measuring 3.6 centimeters on a side traversed by an experimental subject into, out of or within a distinct and specified area of an experimental apparatus (especially such a movement accomplished by the action of appendages such as flagella, limbs, or wings) originated, undertaken, controlled, or accomplished as a result of free will or choice.
- Percentage of CD4 Positive Cells Expressing Interferon Gamma [CMO:0003223] —
- Percentage of CD8 Positive Cells Expressing Interferon Gamma [CMO:0003224] —
- Percentage of Disease Population Developing Relapsing-remitting Experimental Autoimmune Encephalomyelitis During A Period of Time [CMO:0001625] — The number of new cases of relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) appearing in a study population of individuals that already have experimental autoimmune encephalomyelitis during a certain period compared to the total number of individuals in that already-diseased study population, expressed as a percentage. R-EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells where such induction results in a disease characterized by repeated symptomatic attacks followed by complete or almost complete improvement.
- Percentage of Disease Population Displaying Relapsing-remitting Experimental Autoimmune Encephalomyelitis at A Point in Time [CMO:0001626] — The number of individuals in a study population of individuals that already have experimental autoimmune encephalomyelitis which display relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) at a certain point in time compared to the total number of individuals in that already-diseased study population, expressed as a percentage. R-EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells where such induction results in a disease characterized by repeated symptomatic attacks followed by complete or almost complete improvement.
- Percentage of Entries Into A Discrete Space in An Experimental Apparatus [CMO:0000961] — The proportion of the total number of entries into any area of an experimental apparatus in which an organism or experimental subject enters a distinct and specified area of the apparatus, expressed as a percentage.
- Percentage of Experiment Time Spent in A Discrete Space in An Experimental Apparatus [CMO:0000959] — The proportion of the total amount of time that an organism or experimental subject spends in an experimental apparatus which is spent in a distinct and specified area of that apparatus, expressed as a percentage.
- Percentage of Full Platelet Aggregation Generated By Thrombin [CMO:0003682] — This value is calculated from an aggregometry assay curve by measuring the distance between the baseline and maximal aggregation caused by thrombin and dividing by the distance between the baseline [0% aggregation - platelet rich plasma] and 100% aggregation [platelet poor plasma].
- Percentage of Study Population Developing Cerebral Small Vessel Thrombosis and Adjacent Tissue Infarction During A Period of Time [CMO:0003501] — The number of individuals in a study population which develop new instances of cerebral small vessel thromboses and adjacent tissue infarction during a period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Acute Experimental Autoimmune Encephalomyelitis During A Period of Time [CMO:0001859] — The number of new cases of acute experimental autoimmune encephalomyelitis (EAE) appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells. Acute EAE is a variant of EAE having a short, monophasic timecourse of symptoms which are usually severe, followed by complete and stable recovery.
- Percentage of Study Population Developing Anorectal Malformation During A Period of Time [CMO:0002754] — The number of new cases of anorectal malformation appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Anorectal malformations (ARMs) represent a spectrum of congenital anomalies characterized by the obstruction of the anal opening.
- Percentage of Study Population Developing Ascites During A Period of Time [CMO:0003784] — The total number of subjects within a study population which develop ascites during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. Ascites is the pathological accumulation or retention of free fluid within the peritoneal cavity.
- Percentage of Study Population Developing Benign Colorectal Tumors During A Period of Time [CMO:0001803] — The number of new cases of benign colorectal tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Benign colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which are generally stable, treatable, circumscribed (that is, not displaying invasiveness or metastasis), and in a relatively normal state of differentiation, and which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Developing Benign Liver Tumors During A Period of Time [CMO:0001711] — The number of new cases of benign liver tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins. Such a tumor is benign when it is generally stable, treatable, circumscribed, that is, not displaying invasiveness or metastasis, and in a relatively normal state of differentiation.
- Percentage of Study Population Developing Bilateral Renal Agenesis During A Period of Time [CMO:0000942] — The number of new cases of bilateral renal agenesis, the failure to develop both kidneys resulting in a complete lack of kidneys in the individual, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Bilateral Testis Tumors During A Period of Time [CMO:0001264] — The number of new cases of individuals developing tumors in both testes in a study population during a certain period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Cataract During A Period of Time [CMO:0001586] — The number of new cases of cataract appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Cerebral Beta-amyloid Deposits During A Period of Time [CMO:0003499] — The number of individuals in a study population which develop new instances of cerebral beta-amyloid deposits during a period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Cerebral Small Perivascular Bleeds and Beta-amyloid Deposits During A Period of Time [CMO:0003502] — The number of individuals in a study population which develop new instances of cerebral small perivascular bleeds and beta-amyloid deposits during a period of time compared to the total number of individuals in the study population with beta-amyloid deposits, expressed as a percentage.
- Percentage of Study Population Developing Cerebral Small Perivascular Bleeds and No Beta-amyloid Deposits During A Period of Time [CMO:0003503] — The number of individuals in a study population which develop new instances of cerebral small perivascular bleeds and no beta-amyloid deposits during a period of time compared to the total number of individuals in the study population with no beta-amyloid deposits, expressed as a percentage.
- Percentage of Study Population Developing Cerebral Small Perivascular Bleeds During A Period of Time [CMO:0003500] — The number of individuals in a study population which develop new instances of cerebral small perivascular bleeds during a period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Cerebrovascular Lesions During A Period of Time [CMO:0000932] — The number of individuals in a study population which develop new instances of non-tumorous cerebrovascular lesions during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A non-tumorous cerebrovascular lesion is a non-neoplastic, localized, pathological change in the structure of the brain which involves or is caused by a component of the vascular system and/or blood supply of the brain, due to injury or disease; especially one that is circumscribed and well defined.
- Percentage of Study Population Developing Chronic Experimental Arthritis During A Period of Time [CMO:0001456] — The number of new cases of chronic experimental arthritis appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Chronic experimental arthritis refers to artificially induced joint inflammation which persists for a long period of time, especially when characterized by recurrence and/or slow development over time.
- Percentage of Study Population Developing Chronic Experimental Autoimmune Encephalomyelitis During A Period of Time [CMO:0001893] — The number of new cases of chronic experimental autoimmune encephalomyelitis (EAE) appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells. Chronic EAE is a variant of EAE characterized by a long duration and slow, constant progression.
- Percentage of Study Population Developing Chronic Pancreatitis During A Period of Time [CMO:0001213] — The number of new cases of chronic pancreatitis appearing in a study population during a specified period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Colonic Aganglionosis During A Period of Time [CMO:0001839] — The number of new cases of colonic aganglionosis appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Colonic aganglionosis is the absence of parasympathetic ganglion cells in any or all of the myenteric plexus, a network of autonomic nerve fibers within the tunica muscularis of the wall of the alimentary canal in general and of the colon in particular. The colon is the segment of the large intestine between the cecum and the rectum.
- Percentage of Study Population Developing Colorectal Tumors During A Period of Time [CMO:0001801] — The number of new cases of colorectal tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Developing Diabetes Mellitus During A Period of Time [CMO:0001114] — The number of new cases of diabetes mellitus appearing in a study population during a specified period compared to the total number of individuals in the study population, expressed as a percentage. Diabetes mellitus is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance and resulting in hyperglycemia due to decreased glucose tolerance.
- Percentage of Study Population Developing Endometrial Adenocarcinomas During A Period of Time [CMO:0001790] — The number of new cases of endometrial adenocarcinomas appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. An endometrial adenocarcinoma is an abnormal and malignant growth of the epithelial cells of the mucous membrane lining the uterus that results from uncontrolled, progressive multiplication of cells, serves no physiological function, and forms or appears to form glandular structures.
- Percentage of Study Population Developing Endometrioid Carcinoma During A Period of Time [CMO:0001759] — The number of new cases of endometrioid carcinoma appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Endometrioid carcinoma is a malignant new growth occurring in the uterine fundus and ovaries and characterized by glandular patterns resembling those of the endometrium, which is made up of epithelial cells tending to infiltrate surrounding tissues and to give rise to metastases.
- Percentage of Study Population Developing Experimental Arthritis During A Period of Time [CMO:0001453] — The number of new cases of experimental arthritis appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Experimental arthritis is a disease characterized by inflammation of one or more joints, the sites of junction or union between bones, especially those that allow motion of the bones, in which the condition is a result of the artificial induction of joint inflammation.
- Percentage of Study Population Developing Experimental Autoimmune Encephalomyelitis During A Period of Time [CMO:0001047] — The number of new cases of experimental autoimmune encephalomyelitis (EAE) appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells.
- Percentage of Study Population Developing Experimental Autoimmune Neuritis During A Period of Time [CMO:0001522] — The number of new cases of experimental autoimmune neuritis (EAN), inflammation of peripheral nerves caused by an anti-self immune reaction experimentally or artificially triggered by introduction of peripheral nerve tissue or protein components in adjuvant, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Experimental Diabetes Mellitus During A Period of Time [CMO:0001992] — The number of new cases of experimental diabetes mellitus appearing in a study population during a specified period compared to the total number of individuals in the study population, expressed as a percentage. Experimental DM is diabetes induced experimentally by administration of various diabetogenic agents or by removal of all or part of the pancreas.
- Percentage of Study Population Developing Extra-hepatic Metastases During A Period of Time [CMO:0003785] — The number of subjects developing extra-hepatic metastases in a study population during a certain period compared to the total number of subjects in the study population, expressed as a percentage. An extra-hepatic metastasis is a neoplasm transferred from one organ or part of the body to another (not liver) remote from the primary site.
- Percentage of Study Population Developing Glycosuria During A Period of Time [CMO:0003449] — The number of new cases of glycosuria appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Hematuria During A Period of Time [CMO:0001203] — The number of new cases of hematuria, that is blood in the urine, appearing in a study population during a specified period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Hepatocellular Carcinoma During A Period of Time [CMO:0002602] — The number of new cases of hepatocellular carcinoma appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Herpes Simplex Encephalitis During A Period of Time [CMO:0002370] — Any measurement in which the number of individuals in a study population that develop encephalitis resulting from a herpes simplex virus (HSV) infection at within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. HSV encephalitis is an acute (or rarely chronic) inflammatory process of the brain caused by Simplexvirus infections which may be fatal.
- Percentage of Study Population Developing Intestine Tumors During A Period of Time [CMO:0003572] — The number of new cases of intestine tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage, but could be expressed as a ratio. Intestine tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which occur in the intestine, the portion of the alimentary canal extending from the pyloric opening of the stomach to the anus.
- Percentage of Study Population Developing Kidney Edema During A Period of Time [CMO:0002267] — A measurement in which the number of individuals in a study population that develop kidney edema, that is, an abnormal accumulation of fluid in intercellular spaces of the kidney, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Kidney Tubular Degeneration During A Period of Time [CMO:0002270] — A measurement in which the number of individuals in a study population that develop kidney tubular degeneration, that is, deterioration of the renal tubules especially with a resulting loss of function, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Kidney Tubulointerstitial Damage at A Point in Time [CMO:0003650] — A measurement in which the number of individuals in a study population that develop kidney tubulointerstitial damage at a point in time, are compared to the total number of individuals in the study population. Usually expressed as a percentage, but could be expressed as a ratio.
- Percentage of Study Population Developing Kidney Tubulointerstitial Damage During A Period of Time [CMO:0003649] — A measurement in which the number of individuals in a study population that develop kidney tubulointerstitial damage within a determined period of time, are compared to the total number of individuals in the study population. Usually expressed as a percentage, but could be expressed as a ratio.
- Percentage of Study Population Developing Leukemia During A Period of Time [CMO:0001267] — The number of new cases of leukemia, any of a group of progressive, malignant diseases of the blood-forming organs, marked by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Liver Edema During A Period of Time [CMO:0002258] — A measurement in which the number of individuals in a study population that develop liver edema, that is, an abnormal accumulation of fluid in intercellular spaces of the liver, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Liver Hyperemia During A Period of Time [CMO:0002261] — A measurement in which the number of individuals in a study population that develop liver hyperemia, that is, an abnormal accumulation of blood in the liver, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Liver Parenchymal Degeneration During A Period of Time [CMO:0002264] — A measurement in which the number of individuals in a study population that develop liver parenchymal degeneration, that is, deterioration of the functional (as opposed to supporting or connective) tissue or cells of the liver especially with a resulting loss of function, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Liver Tumors During A Period of Time [CMO:0001594] — The number of new cases of liver tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins.
- Percentage of Study Population Developing Lung Tumors During A Period of Time [CMO:0003429] — The number of individuals in a study population which develop new instances of lung tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Developing Malignant Colorectal Tumors During A Period of Time [CMO:0001802] — The number of new cases of malignant colorectal tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Malignant colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Developing Malignant Liver Tumors During A Period of Time [CMO:0001712] — The number of new cases of malignant liver tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins. Such a tumor is malignant when it displays the properties of anaplasia, invasiveness and metastasis.
- Percentage of Study Population Developing Mammary Tumors During A Period of Time [CMO:0000948] — The number of individuals in a study population which develop new instances of mammary tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Developing Meconium Ileus During A Period of Time [CMO:0003881] — This is the number of new cases of meconium ileus appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Meconium ileus is intestinal obstruction due to inspissated meconium in the distal ileum and cecum, which develops in utero and presents shortly after birth as a failure to pass meconium.
- Percentage of Study Population Developing Metastatic Liver Tumors During A Period of Time [CMO:0003871] — The number of new cases of metastatic liver tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A metastatic liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in, but originating distant to the liver.
- Percentage of Study Population Developing Metastatic Lung Tumors During A Period of Time [CMO:0003432] — The number of individuals in a study population which develop metastatic lung tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A metastatic tumor in the lung is a secondary abnormal growth of tissue resulting from the spread of cancer cells to the lung from the place where they first formed.
- Percentage of Study Population Developing Myeloid Leukemia During A Period of Time [CMO:0002277] — The number of new cases of myeloid leukemia, a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid (that is, non-lymphocytic) cells in the bone marrow and the accumulation of these cells in the bone marrow and/or blood, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Peritoneal Carcinomatosis During A Period of Time [CMO:0003780] — The total number of subjects within a study population which develop peritoneal carcinomatosis during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. Peritoneal carcinomatosis is multiple tumorsusually metastatic, growing in or on the peritoneum, a serous membrane that lines the peritoneal cavity .
- Percentage of Study Population Developing Pituitary Gland Hyperplastic Lesions During A Period of Time [CMO:0001622] — The number of new cases of pituitary gland hyperplastic lesions appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A pituitary gland hyperplastic lesion is a localized pathological change, especially one that is circumscribed and well defined, in structure of the pituitary gland, due to injury or disease and characterized by an abnormal increase in the number of normal cells in normal arrangement in the gland resulting in an increase in the size of the tissue. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Percentage of Study Population Developing Pituitary Tumors During A Period of Time [CMO:0001029] — The number of individuals in a study population which develop new instances of pituitary gland tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Developing Pituitary Tumors That Invade the Glandular Capsule During A Period of Time [CMO:0001619] — The number of individuals in a study population which develop new instances of pituitary gland tumors in which neoplastic tissue grows into and/or through the membrane surrounding the gland during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function. The pituitary gland is a small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Percentage of Study Population Developing Pituitary Tumors That Replace A Portion of the Gland During A Period of Time [CMO:0001618] — The number of individuals in a study population which develop new instances of pituitary gland tumors in which the neoplastic tissue only partially eliminates and takes the place of the normal tissue in the pituitary gland, resulting in a mix of neoplastic and normal tissues, during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function. The pituitary gland is a small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Percentage of Study Population Developing Pituitary Tumors That Replace the Entire Gland During A Period of Time [CMO:0001617] — The number of individuals in a study population which develop new instances of pituitary gland tumors in which the neoplastic tissue completely eliminates and takes the place of all of the normal tissue in the pituitary gland during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function. The pituitary gland is a small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Percentage of Study Population Developing Poorly Differentiated Malignant Colorectal Tumors During A Period of Time [CMO:0002071] — The number of new cases of poorly differentiated malignant colorectal tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Poorly differentiated malignant colorectal tumors are abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and do not display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Percentage of Study Population Developing Prostate Tumorous Lesions During A Period of Time [CMO:0000933] — The number of individuals in a study population which develop new instances of prostate tumorous lesions during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Percentage of Study Population Developing Prostate Tumors During A Period of Time [CMO:0000945] — The number of individuals in a study population which develop new instances of prostate tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Developing Pyometritis During A Period of Time [CMO:0002012] — Any measurement in which the number of individuals in a study population that develop pyometritis within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. Pyometritis is a suppurative inflammation of the uterus.
- Percentage of Study Population Developing Radiation Pneumonitis During A Period of Time [CMO:0003722] — The total number of subjects within a study population which develop radiation pneumonitis during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. Radiation pneumonitis is inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
- Percentage of Study Population Developing Radiation-induced Bone Marrow Disease During A Period of Time [CMO:0003723] — The total number of subjects within a study population which develop radiation-induced bone marrow dysfunction during a specified period of time divided by the total number of individuals in the study population, expressed as a percentage. Radiation-induced bone marrow dysfunction is hematopoietic toxicity due to the harmful effects of radiation.
- Percentage of Study Population Developing Relapsing-remitting Experimental Autoimmune Encephalomyelitis During A Period of Time [CMO:0001402] — The number of new cases of relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. R-EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells where such induction results in a disease characterized by repeated symptomatic attacks followed by complete or almost complete improvement.
- Percentage of Study Population Developing Renal Vascular Pathology During A Period of Time [CMO:0003504] — The number of individuals in a study population which develop new instances of renal vascular pathology during a period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Retinopathy During A Period of Time [CMO:0002453] — The number of new cases of retinopathy appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Retinopathy is a noninflammatory degenerative disease of the retina.
- Percentage of Study Population Developing Spleen Fibrosis During A Period of Time [CMO:0002273] — A measurement in which the number of individuals in a study population that develop fibrosis of the spleen, that is, an abnormal condition in which fibrous connective tissue spreads over or replaces the normal tissue in the spleen, within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Developing Stomach Tumors During A Period of Time [CMO:0002285] — The number of individuals in a study population which develop new instances of stomach tumors during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Subcutaneous Tumors During A Period of Time [CMO:0003387] — The number of new cases of individuals developing subcutaneous tumors in a study population during a certain period of time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing T-cell Lymphomas During A Period of Time [CMO:0001911] — The number of new cases of T-cell lymphoma appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. T-cell lymphoma refers to a heterogeneous group of usually malignant lymphoid neoplasms that occur as circumscribed solid tumors and that are composed of T lymphocytes. T lymphocytes are white blood cells that complete maturation in the thymus and that have various roles in the immune system, including the identification of specific foreign antigens in the body, the mediation of cellular immune responses, and the activation and deactivation of other immune cells.
- Percentage of Study Population Developing Testis Tumors During A Period of Time [CMO:0001261] — The number of new cases of individuals developing one or more testis tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Toxoplasma Gondii Brain Cysts During A Period of Time [CMO:0002029] — The number of new cases of Toxoplasma gondii brain cysts, small capsulelike sacs enclosing colonies of Toxoplasma gondii in the brain, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Toxoplasma gondii is a sporozoan species that is an intracellular parasite in a variety of vertebrates and is the causative agent of toxoplasmosis.
- Percentage of Study Population Developing Trigeminal Nerve Neurilemmomas During A Period of Time [CMO:0002017] — Any measurement in which the number of individuals in a study population that develop trigeminal nerve neurilemmomas within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A trigeminal nerve neurilemmoma is a tumor originating in the myelin sheath of the trigeminal nerve, either of the fifth pair of cranial nerves which function as the chief sensory nerves of the face and the motor nerves of the muscles of mastication.
- Percentage of Study Population Developing Type 1 Diabetes Mellitus During A Period of Time [CMO:0001136] — The number of new cases of type 1 diabetes mellitus (T1DM) appearing in a study population during a specified period compared to the total number of individuals in the study population, expressed as a percentage. T1DM is a form of diabetes mellitus which results from the autoimmune destruction of beta cells of the pancreatic islets of Langerhans.
- Percentage of Study Population Developing Type 2 Diabetes Mellitus During A Period of Time [CMO:0001137] — The number of new cases of type 2 diabetes mellitus appearing in a study population during a specified period compared to the total number of individuals in the study population, expressed as a percentage. T2DM is a form of diabetes often, although not universally, associated with obesity, insulin resistance, hyperlipidemia(s) and cardiovascular symptoms such as hypertension.
- Percentage of Study Population Developing Unilateral Left-sided Renal Agenesis During A Period of Time [CMO:0002032] — The number of new cases of unilateral left-sided renal agenesis, the failure to develop the left kidney, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Unilateral Renal Agenesis During A Period of Time [CMO:0000940] — The number of new cases of unilateral renal agenesis, the failure to develop one of the kidneys, appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Developing Ventral Prostate Tumorous Lesions During A Period of Time [CMO:0000943] — The number of individuals in a study population which develop new instances of tumorous lesions of the ventral prostate during a certain period compared to the total number of individuals in the study population, expressed as a percentage. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Percentage of Study Population Developing Ventral Prostate Tumorous Lesions With A Solid Structure During A Period of Time [CMO:0003687] — The number of individuals in a study population which develop new instances of ventral prostate tumorous lesions with a solid structure during a certain period of time compared to the total number of individuals in the study population, expressed as a percentage. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histollogicaly normal cells.
- Percentage of Study Population Developing Ventral Prostate Tumorous Lesions With Round, Irregular Size Nuclei During A Period of Time [CMO:0003688] — The number of individuals in a study population which develop new instances of ventral prostate tumorous lesions with round, irregular size nuclei during a certain period of time compared to the total number of individuals in the study population, expressed as a percentage. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histollogicaly normal cells.
- Percentage of Study Population Developing Well Differentiated Malignant Colorectal Tumors During A Period of Time [CMO:0002072] — The number of new cases of well differentiated malignant colorectal tumors appearing in a study population during a certain period compared to the total number of individuals in the study population, expressed as a percentage. Well differentiated malignant colorectal tumors are abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, but which also display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Percentage of Study Population Displaying Acute Experimental Autoimmune Encephalomyelitis at A Point in Time [CMO:0001860] — The number of individuals in a study population which display experimental autoimmune encephalomyelitis (EAE) at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells. Acute EAE is a variant of EAE having a short, monophasic timecourse of symptoms which are usually severe, followed by complete and stable recovery.
- Percentage of Study Population Displaying Anorectal Malformation at A Point in Time [CMO:0002755] — The number of individuals in a study population which display, i.e., are manifesting symptoms of or have been diagnosed with, anorectal malformation at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Anorectal malformations (ARMs) represent a spectrum of congenital anomalies characterized by the obstruction of the anal opening.
- Percentage of Study Population Displaying Benign Colorectal Tumors at A Point in Time [CMO:0001806] — The number of individuals in a study population which display benign colorectal tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Benign colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which are generally stable, treatable, circumscribed (that is, not displaying invasiveness or metastasis), and in a relatively normal state of differentiation, and which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Displaying Benign Liver Tumors at A Point in Time [CMO:0001713] — The number of individuals in a study population which display benign liver tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins. Such a tumor is benign when it is generally stable, treatable, circumscribed, that is, not displaying invasiveness or metastasis, and in a relatively normal state of differentiation.
- Percentage of Study Population Displaying Bilateral Renal Agenesis at A Point in Time [CMO:0000941] — The number of individuals in a study population which display bilateral renal agenesis, the failure to develop both kidneys resulting in a complete lack of kidneys in the individual, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Bilateral Testis Tumors at A Point in Time [CMO:0001265] — The number of individuals in a study population which display tumors in both testes at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Cataract at A Point in Time [CMO:0001587] — The number of individuals in a study population which display cataract at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Cerebrovascular Lesions at A Point in Time [CMO:0000925] — The number of individuals in a study population which display non-tumorous cerebrovascular lesions at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A non-tumorous cerebrovascular lesion is a non-neoplastic, localized, pathological change in the structure of the brain which involves or is caused by a component of the vascular system and/or blood supply of the brain, due to injury or disease; especially one that is circumscribed and well defined.
- Percentage of Study Population Displaying Chronic Experimental Arthritis at A Point in Time [CMO:0001457] — The number of individuals in a study population which display chronic experimental arthritis at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Chronic experimental arthritis refers to artificially induced joint inflammation which persists for a long period of time, especially when characterized by recurrence and/or slow development over time.
- Percentage of Study Population Displaying Chronic Experimental Autoimmune Encephalomyelitis at A Point in Time [CMO:0001892] — A measurement in which the number of individuals in a study population that display, i.e., are manifesting symptoms of or have been diagnosed with, chronic experimental autoimmune encephalomyelitis (EAE) at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells. Chronic EAE is a variant of EAE characterized by a long duration and slow, constant progression.
- Percentage of Study Population Displaying Chronic Pancreatitis at A Point in Time [CMO:0001214] — The number of individuals in a study population which display chronic pancreatitis at a specified point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Colonic Aganglionosis at A Point in Time [CMO:0001838] — The number of individuals in a study population which display colonic aganglionosis at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Colonic aganglionosis is the absence of parasympathetic ganglion cells in any or all of the myenteric plexus, a network of autonomic nerve fibers within the tunica muscularis of the wall of the alimentary canal in general and of the colon in particular. The colon is the segment of the large intestine between the cecum and the rectum.
- Percentage of Study Population Displaying Colorectal Tumors at A Point in Time [CMO:0001804] — The number of individuals in a study population which display colorectal tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Displaying Diabetes Mellitus at A Point in Time [CMO:0001115] — The number of individuals in a study population which display diabetes mellitus at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Diabetes mellitus is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance and resulting in hyperglycemia due to decreased glucose tolerance.
- Percentage of Study Population Displaying Endometrial Adenocarcinomas at A Point in Time [CMO:0001791] — The number of individuals in a study population which display endometrial adenocarcinomas at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. An endometrial adenocarcinoma is an abnormal and malignant growth of the epithelial cells of the mucous membrane lining the uterus that results from uncontrolled, progressive multiplication of cells, serves no physiological function, and forms or appears to form glandular structures.
- Percentage of Study Population Displaying Endometrioid Carcinoma at A Point in Time [CMO:0001760] — The number of individuals in a study population which display endometrioid carcinoma at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Endometrioid carcinoma is a malignant new growth occurring in the uterine fundus and ovaries and characterized by glandular patterns resembling those of the endometrium, which is made up of epithelial cells tending to infiltrate surrounding tissues and to give rise to metastases.
- Percentage of Study Population Displaying Experimental Arthritis at A Point in Time [CMO:0001454] — The number of individuals in a study population which display experimental arthritis at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Experimental arthritis is a disease characterized by inflammation of one or more joints, the sites of junction or union between bones, especially those that allow motion of the bones, in which the condition is a result of the artificial induction of joint inflammation.
- Percentage of Study Population Displaying Experimental Autoimmune Encephalomyelitis at A Point in Time [CMO:0001048] — The number of individuals in a study population which display experimental autoimmune encephalomyelitis (EAE) at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells.
- Percentage of Study Population Displaying Experimental Autoimmune Neuritis at A Point in Time [CMO:0001523] — The number of individuals in a study population which display experimental autoimmune neuritis (EAN), inflammation of peripheral nerves caused by an anti-self immune reaction experimentally or artificially triggered by introduction of peripheral nerve tissue or protein components in adjuvant, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Experimental Diabetes Mellitus at A Point in Time [CMO:0001993] — The number of individuals in a study population which display experimental diabetes mellitus at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Experimental DM is diabetes induced experimentally by administration of various diabetogenic agents or by removal of all or part of the pancreas.
- Percentage of Study Population Displaying Glycosuria at A Point in Time [CMO:0003450] — The number of individuals in a study population which display glycosuria at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Hematuria at A Point in Time [CMO:0001204] — The number of individuals in a study population which display hematuria, that is blood in the urine, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Hepatocellular Carcinoma at A Point in Time [CMO:0002601] — The number of individuals in a study population which display hepatocellular carcinoma at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Herpes Simplex Encephalitis at A Point in Time [CMO:0002369] — Any measurement in which the number of individuals in a study population that display encephalitis resulting from a herpes simplex virus (HSV) infection at a specified point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. HSV encephalitis is an acute (or rarely chronic) inflammatory process of the brain caused by Simplexvirus infections which may be fatal.
- Percentage of Study Population Displaying Intestine Tumors at A Point in Time [CMO:0003573] — The number of individuals in a study population which display intestine tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage or ratio. Intestine tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which occur in the intestine, the portion of the alimentary canal extending from the pyloric opening of the stomach to the anus.
- Percentage of Study Population Displaying Kidney Edema at A Point in Time [CMO:0002266] — A measurement in which the number of individuals in a study population that display kidney edema, that is, an abnormal accumulation of fluid in intercellular spaces of the kidney, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Kidney Tubular Degeneration at A Point in Time [CMO:0002269] — A measurement in which the number of individuals in a study population that display kidney tubular degeneration, that is, deterioration of the renal tubules especially with a resulting loss of function, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Leukemia at A Point in Time [CMO:0001268] — The number of individuals in a study population which display leukemia, any of a group of progressive, malignant diseases of the blood-forming organs, marked by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Liver Edema at A Point in Time [CMO:0002259] — A measurement in which the number of individuals in a study population that display liver edema, that is, an abnormal accumulation of fluid in intercellular spaces of the liver, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Liver Hyperemia at A Point in Time [CMO:0002260] — A measurement in which the number of individuals in a study population that display liver hyperemia, that is, an abnormal accumulation of blood in the liver, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Liver Parenchymal Degeneration at A Point in Time [CMO:0002263] — A measurement in which the number of individuals in a study population that display liver parenchymal degeneration, that is, deterioration of the functional (as opposed to supporting or connective) tissue or cells of the liver especially with a resulting loss of function, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Liver Tumors at A Point in Time [CMO:0001595] — The number of individuals in a study population which display liver tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins.
- Percentage of Study Population Displaying Lung Tumors at A Point in Time [CMO:0003430] — The number of individuals in a study population which display tumors of the lung at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Displaying Malignant Colorectal Tumors at A Point in Time [CMO:0001805] — The number of individuals in a study population which display malignant colorectal tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Malignant colorectal tumors are abnormal growths of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and which occur in the large intestine, the distal portion of the alimentary canal, especially in the colon and/or rectum, the segment of the large intestine between the cecum and the anal canal.
- Percentage of Study Population Displaying Malignant Liver Tumors at A Point in Time [CMO:0001714] — The number of individuals in a study population which display malignant liver tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in and composed of cells specific to the liver, the large, dark-red organ located in the cranial portion of the abdomen of vertebrates, just behind or below the diaphragm, the functions of which include storage and filtration of blood; secretion of bile; detoxification of noxious substances; conversion of sugars into glycogen; synthesis and breakdown of fats and temporary storage of fatty acids; and synthesis of serum proteins. Such a tumor is malignant when it displays the properties of anaplasia, invasiveness and metastasis.
- Percentage of Study Population Displaying Mammary Tumors at A Point in Time [CMO:0000947] — The number of individuals in a study population which display tumors of the mammary gland compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Displaying Metastatic Liver Tumors at A Point in Time [CMO:0003872] — This is a measurement of the number of individuals in a study population which display metastatic liver tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A metastatic liver tumor is a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive occurring in, but originating distant to the liver.
- Percentage of Study Population Displaying Metastatic Tumors in the Lung at A Point in Time [CMO:0003431] — The number of individuals in a study population which display metastatic tumors in the lung at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A metastatic tumor in the lung is a secondary abnormal growth of tissue resulting from the spread of cancer cells to the lung from the place where they first formed.
- Percentage of Study Population Displaying Myeloid Leukemia at A Point in Time [CMO:0002276] — The number of individuals in a study population which display myeloid leukemia, a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid (that is, non-lymphocytic) cells in the bone marrow and the accumulation of these cells in the bone marrow and/or blood, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Pituitary Gland Hyperplastic Lesions at A Point in Time [CMO:0001623] — The number of individuals in a study population which display pituitary gland hyperplastic lesions at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A pituitary gland hyperplastic lesion is a localized pathological change, especially one that is circumscribed and well defined, in structure of the pituitary gland, due to injury or disease and characterized by an abnormal increase in the number of normal cells in normal arrangement in the gland resulting in an increase in the size of the tissue. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Percentage of Study Population Displaying Pituitary Tumors at A Point in Time [CMO:0001030] — The number of individuals in a study population which display tumors of the pituitary gland compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Displaying Poorly Differentiated Malignant Colorectal Tumors at A Point in Time [CMO:0002074] — The number of individuals in a study population which display poorly differentiated malignant colorectal tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Poorly differentiated malignant colorectal tumors are abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and do not display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Percentage of Study Population Displaying Prostate Tumorous Lesions at A Point in Time [CMO:0000883] — The number of individuals in a study population which display prostate tumorous lesions at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Percentage of Study Population Displaying Prostate Tumors at A Point in Time [CMO:0000944] — The number of individuals in a study population which display tumors of the prostate gland compared to the total number of individuals in the study population, expressed as a percentage. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Percentage of Study Population Displaying Pyometritis at A Point in Time [CMO:0002011] — Any measurement in which the number of individuals in a study population that display pyometritis at a specified point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. Pyometritis is a suppurative inflammation of the uterus.
- Percentage of Study Population Displaying Relapsing-remitting Experimental Autoimmune Encephalomyelitis at A Point in Time [CMO:0001403] — The number of individuals in a study population which display relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE) at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. R-EAE is an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells where such induction results in a disease characterized by repeated symptomatic attacks followed by complete or almost complete improvement.
- Percentage of Study Population Displaying Retinopathy at A Point in Time [CMO:0002452] — The number of individuals in a study population which display, i.e., are manifesting symptoms of or have been diagnosed with, retinopathy at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Retinopathy is a noninflammatory degenerative disease of the retina.
- Percentage of Study Population Displaying Spleen Fibrosis at A Point in Time [CMO:0002272] — A measurement in which the number of individuals in a study population that display fibrosis of the spleen, that is, an abnormal condition in which fibrous connective tissue spreads over or replaces the normal tissue in the spleen, at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Percentage of Study Population Displaying Stomach Tumors at A Point in Time [CMO:0002284] — The number of individuals in a study population which display stomach tumors at a specified point in time, compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying T-cell Lymphomas at A Point in Time [CMO:0001910] — The number of individuals in a study population which display, i.e., are manifesting symptoms of or have been diagnosed with, T-cell lymphomas at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. T-cell lymphoma refers to a heterogeneous group of usually malignant lymphoid neoplasms that occur as circumscribed solid tumors and that are composed of T lymphocytes. T lymphocytes are white blood cells that complete maturation in the thymus and that have various roles in the immune system, including the identification of specific foreign antigens in the body, the mediation of cellular immune responses, and the activation and deactivation of other immune cells.
- Percentage of Study Population Displaying Testis Tumors at A Point in Time [CMO:0001262] — The number of individuals in a study population which display one or more testis tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Toxoplasma Gondii Brain Cysts at A Point in Time [CMO:0002028] — The number of individuals in a study population which display Toxoplasma gondii brain cysts, small capsulelike sacs enclosing colonies of Toxoplasma gondii in the brain, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Toxoplasma gondii is a sporozoan species that is an intracellular parasite in a variety of vertebrates and is the causative agent of toxoplasmosis.
- Percentage of Study Population Displaying Trigeminal Nerve Neurilemmomas at A Point in Time [CMO:0002016] — Any measurement in which the number of individuals in a study population that display trigeminal nerve neurilemmomas at a point in time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A trigeminal nerve neurilemmoma is a tumor originating in the myelin sheath of the trigeminal nerve, either of the fifth pair of cranial nerves which function as the chief sensory nerves of the face and the motor nerves of the muscles of mastication.
- Percentage of Study Population Displaying Type 1 Diabetes Mellitus at A Point in Time [CMO:0001138] — The number of individuals in a study population which display type 1 diabetes mellitus (T1DM) at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. T1DM is a form of diabetes mellitus which results from the autoimmune destruction of beta cells of the pancreatic islets of Langerhans.
- Percentage of Study Population Displaying Type 2 Diabetes Mellitus at A Point in Time [CMO:0001139] — The number of individuals in a study population which display type 2 diabetes mellitus (T2DM) at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. T2DM is a form of diabetes often, although not universally, associated with obesity, insulin resistance, hyperlipidemia(s) and cardiovascular symptoms such as hypertension.
- Percentage of Study Population Displaying Unilateral Left-sided Renal Agenesis at A Point in Time [CMO:0002033] — The number of individuals in a study population which display unilateral left-sided renal agenesis, the failure to develop the left kidney, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Unilateral Renal Agenesis at A Point in Time [CMO:0000939] — The number of individuals in a study population which display unilateral renal agenesis, the failure to develop one of the kidneys, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Percentage of Study Population Displaying Ventral Prostate Tumorous Lesions at A Point in Time [CMO:0000893] — The number of individuals in a study population which display tumorous lesions of the ventral lobe of the prostate at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Percentage of Study Population Displaying Well Differentiated Malignant Colorectal Tumors at A Point in Time [CMO:0002073] — The number of individuals in a study population which display well differentiated malignant colorectal tumors at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage. Well differentiated malignant colorectal tumors are abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, but which also display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Percentage of Study Population With Hydronephrosis Developing Hematuria During A Period of Time [CMO:0001205] — The number of new cases of hematuria, that is blood in the urine, appearing in a study population with preexisting hydronephrosis, that is, dilation of the pelvis and calices of one or both kidneys because of the accumulation of urine resulting from obstruction to urine outflow, during a specified period compared to the total number of individuals in that study population, expressed as a percentage.
- Percentage of Study Population With Hydronephrosis Displaying Hematuria at A Point in Time [CMO:0001206] — The number of individuals in a study population with preexisting hydronephrosis, that is, dilation of the pelvis and calices of one or both kidneys because of the accumulation of urine resulting from obstruction to urine outflow, which display hematuria, that is blood in the urine, at a certain point in time compared to the total number of individuals in the study population, expressed as a percentage.
- Peripheral Nervous System Measurement [CMO:0003922] — This any measurement of the peripheral nervous system, a major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands.
- Peripheral Nervous System Molecular Composition Measurement [CMO:0003924] — This is any quantitation of the molecules, atoms and/or ions which constitute the chemical make-up of a designated part of the peripheral nervous system, a major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands.
- Peripheral Nervous System Morphological Measurement [CMO:0003923] — This is any measurement of the physical form or structure of the peripheral nervous system, a major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands.
- Peripheral Nervous System Ribonucleic Acid Composition Measurement [CMO:0003925] — This is any measurement of the absolute or relative amount(s) of one or more of the ribonucleic acids (RNAs) of which the tissue of the peripheral nervous system is formed or composed.
- Peripheral Retina Horizontal Cell Count to Area Ratio [CMO:0003561] — A calculated measurement in which the number of horizontal cells in the peripheral retina is divided by the total area of the peripheral retina. A horizontal cell is a neuron that laterally connects other neurons in the inner nuclear layer of the retina.
- Peripheral Retina Rod Bipolar Cell Count to Area Ratio [CMO:0003565] — A calculated measurement in which the number of rod bipolar cells in the peripheral retina is divided by the total area of the peripheral retina. A rod bipolar cell is a neuron that is synapsed by rod photoreceptor cells but not by cone photoreceptor cells.
- Phenylephrine Response/sensitivity Measurement [CMO:0000739] — Measurement of an organism's, organ's, tissue's or cell's capacity to respond, such as by a change in activity, state or condition, to phenylephrine (PE), the phenylethanolamine with IUPAC name (R)-3-[-1-hydroxy-2-(methylamino)ethyl]phenol and formula C9H13NO2 that acts as a selective alpha1-adrenergic receptor agonist, decongestant and vasoconstrictor.
- Phenylephrine-induced Blood Vessel Contractile Force Expressed as Percent of Contractile Force Generated By Potassium Chloride [CMO:0003664] — A calculated measurement in which the contractile force of a blood vessel in response to a specified dosage of phenylephrine is divided by the contractile force exerted by that vessel in the presence of potassium chloride and the result expressed as a percentage. Phenylephrine is an adrenergic drug that is a powerful vasoconstrictor.
- Phenylephrine-induced Blood Vessel Contractile Force Expressed as Percent of Force at Baseline [CMO:0002459] — A calculated measurement in which the difference between the contractile force of a blood vessel in response to a specified dosage of phenylephrine and the baseline contractile force exerted by that vessel in the absence of any external stimuli, is divided by the baseline contractile force measurement and the result expressed as a percentage. Phenylephrine is an adrenergic drug that is a powerful vasoconstrictor.
- Photopic A Wave Amplitude of ERG Waveform [CMO:0003707] — Electroretinographic photopic measurement targets cone-pathway function made from the light-adapted eye. The amplitude of the a-wave is typically measured from the pre-stimulus baseline (0 µV) to the trough of the a-wave. Under photopic (light-adapted) conditions, the a-wave is generated by cone photoreceptors, with additional contributions from OFF-type bipolar cells.
- Photopic B Wave Amplitude of ERG Waveform [CMO:0003702] — Electroretinographic photopic measurement targets cone-pathway function made from the light-adapted eye. The amplitude of the b-wave is measured from the trough of the a-wave to the following peak of the b-wave. The b-wave is generated by a combination of ON- and OFF-type bipolar cells in photopic measurement.
- Photoreceptor Inner Segment Thickness [CMO:0003669] — This is a measurement of the inner segment of a photoreceptor. The inner segment connects the outer segment and synapse and is filled with organelles such as the ER, Golgi, and mitochondria, where much of metabolism and regulation of membrane potential takes place.
- Pigmented Coat/hair Area to Total Coat/hair Area Ratio [CMO:0001810] — A calculated measurement in which the value representing the two-dimensional extent of the planar region of the body surface occupied by hair, wool, or fur (cylindrical, keratinized, often pigmented filaments characteristically growing from the epidermis of a mammal) containing proteins or other substances which give that hair the appearance of color, is divided by the value representing the entirety of the two-dimensional extent of the planar region of the body surface of the organism occupied by hair, wool, or fur with or without color, and presented as a ratio, fraction, quotient or percentage. Color is property of a surface or substance due to absorption of certain light rays and reflection of others within the range of wavelengths (roughly 370-760 nm) adequate to excite the retinal receptors.
- Pigmented Dorsal Coat/hair Area to Total Dorsal Coat/hair Area Ratio [CMO:0001811] — A calculated measurement in which the value representing the two-dimensional extent of the planar region of the dorsal half of the body surface occupied by hair, wool, or fur (cylindrical, keratinized, often pigmented filaments characteristically growing from the epidermis of a mammal) containing proteins or other substances which give that hair the appearance of color, is divided by the value representing the entirety of the two-dimensional extent of the planar region of the dorsal half of the body surface of the organism occupied by hair, wool, or fur with or without color, and presented as a ratio, fraction, quotient or percentage. The dorsal half of the body is the approximately fifty percent of the body closest to the back and, in vertebrates, containing the spine. Color is property of a surface or substance due to absorption of certain light rays and reflection of others within the range of wavelengths (roughly 370-760 nm) adequate to excite the retinal receptors.
- Pigmented Ventral Coat/hair Area to Total Ventral Coat/hair Area Ratio [CMO:0001812] — A calculated measurement in which the value representing the two-dimensional extent of the planar region of the ventral half of the body surface occupied by hair, wool, or fur (cylindrical, keratinized, often pigmented filaments characteristically growing from the epidermis of a mammal) containing proteins or other substances which give that hair the appearance of color, is divided by the value representing the entirety of the two-dimensional extent of the planar region of the ventral half of the body surface of the organism occupied by hair, wool, or fur with or without color, and presented as a ratio, fraction, quotient or percentage. The ventral half of the body is the approximately fifty percent of the body that is closest to the anterior aspect of the human body or the lower surface of the body of an animal, and in vertebrates, furthest from the spine. Color is property of a surface or substance due to absorption of certain light rays and reflection of others within the range of wavelengths (roughly 370-760 nm) adequate to excite the retinal receptors.
- Pineal Body Ribonucleic Acid Composition Measurement [CMO:0003307] —
- Pituicyte Count [CMO:0001756] — The enumeration, i.e. measurement of the total number, of pituicytes, the glial-type cells of the posterior pituitary whose main role is to assist in the storage and release of neurohypophysial hormones such as oxytocin and vasopressin, in a specified sample of pituitary gland, the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituicyte Measurement [CMO:0002163] — Any value resulting from the quantification of a morphological or physiological parameter of a pituicyte, a glial-type cell of the posterior pituitary whose main role is to assist in the storage and release of neurohypophysial hormones such as oxytocin and vasopressin.
- Pituitary Gland Dry Weight [CMO:0000852] — The weight of the pituitary gland after desiccation. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Hyperplastic Lesion Incidence/prevalence Measurement [CMO:0001621] — Any measurement in which the number of individuals in a study population that display pituitary gland hyperplastic lesions at a point in time or develop pituitary gland hyperplastic lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A pituitary gland hyperplastic lesion is a localized pathological change, especially one that is circumscribed and well defined, in structure of the pituitary gland, due to injury or disease and characterized by an abnormal increase in the number of normal cells in normal arrangement in the gland resulting in an increase in the size of the tissue. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Hyperplastic Lesion Measurement [CMO:0001620] — Any measurement of a localized pathological change, especially one that is circumscribed and well defined, in structure of the pituitary gland, due to injury or disease and characterized by an abnormal increase in the number of normal cells in normal arrangement in the gland resulting in an increase in the size of the tissue. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Measurement [CMO:0002167] — Any value resulting from the quantification of a morphological or physiological parameter of all or part of the pituitary gland, the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Morphological Measurement [CMO:0000614] — Measurement of the physical form or structure of the pituitary gland, the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Ribonucleic Acid Composition Measurement [CMO:0003304] —
- Pituitary Gland Tumorous Lesion Incidence/prevalence Measurement [CMO:0001624] — Any measurement in which the number of individuals in a study population that display pituitary gland tumorous lesions at a point in time or develop pituitary gland tumorous lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Tumorous Lesion Measurement [CMO:0001034] — Measurement of a pituitary gland lesion which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. The pituitary gland is the gland located at the base of the brain in vertebrates that produces a number of hormones, including those that regulate growth and reproductive functions. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Pituitary Gland Weight [CMO:0000615] — The weight of the pituitary gland, the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Gland Weight to Body Weight Ratio [CMO:0000617] —
- Pituitary Gland Wet Weight [CMO:0000853] — The weight of the pituitary gland after removal from the body but without desiccation. The pituitary gland is the small, oval endocrine gland attached to the base of the vertebrate brain and consisting of an anterior and posterior lobe, the secretions of which control the other endocrine glands and influence growth, metabolism, and maturation.
- Pituitary Tumor Diameter [CMO:0001033] — The length of a transverse line moving from side to side through the center of a tumor located in the pituitary gland.
- Pituitary Tumor Growth Rate [CMO:0001027] — The change is size between two points in time for a tumor found within the pituitary gland.
- Pituitary Tumor Incidence/prevalence Measurement [CMO:0001028] — A measurement in which the number of individuals in a study population displaying one or more tumors of the pituitary gland at a point in time or developing such growths within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumor is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Pituitary Tumor Measurement [CMO:0001025] — Measurement of an abnormal growth of tissue in the pituitary gland resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Pituitary Tumor Number [CMO:0001031] — The number of tumors found within the pituitary gland.
- Pituitary Tumor Weight [CMO:0001032] — The weight of a tumor found within a pituitary gland.
- Placenta Dry Weight [CMO:0002089] — The heaviness of the placenta, that is, the degree to which it is drawn to the earth by gravity, measured after desiccation.
- Placenta Measurement [CMO:0002085] — Any measurement of the placenta, the membranous vascular organ in female mammals that permits metabolic interchange between fetus and mother. It develops during pregnancy from the chorion of the embryo and the decidua basalis of the maternal uterus and is expelled following birth.
- Placenta Morphological Measurement [CMO:0002086] — Any measurement of the physical form or structure of the placenta, the membranous vascular organ in female mammals that permits metabolic interchange between fetus and mother. It develops during pregnancy from the chorion of the embryo and the decidua basalis of the maternal uterus and is expelled following birth.
- Placenta Ribonucleic Acid Composition Measurement [CMO:0003265] —
- Placenta Weight [CMO:0002087] — The heaviness of the placenta, that is, the degree to which it is drawn to the earth by gravity.
- Placenta Weight at Gestational Day 20 [CMO:0002090] — The heaviness of the placenta, i.e., the degree to which it is drawn to the earth by gravity, measured on the 21st day after insemination.
- Placenta Wet Weight [CMO:0002088] — The heaviness of the placenta, that is, the degree to which it is drawn to the earth by gravity, measured after removal from the body but without desiccation.
- Plasma 11-dehydrocorticosterone Level [CMO:0003510] — The amount of 11-dehydrocorticosterone, an 11-oxo steroid that is corticosterone in which the hydroxy substituent at the 11beta position has been oxidized to give the corresponding ketone, found in a specific volume of plasma.
- Plasma 8-epi-prostaglandin F2alpha Level [CMO:0003406] — Measurement of the amount of 8-epi-prostaglandin F2alpha, an isoprostane that is prostaglandin F2alpha having inverted stereochemistry at the 8-position., in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Acetaminophen Level [CMO:0002469] — Measurement of the amount of acetaminophen, an analgesic and antipyretic with effects similar to aspirin but only weakly anti-inflammatory, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Acetaminophen Level Area Under Curve [CMO:0002473] — A calculated measurement in which a series of measurements of the amount of acetaminophen in a specified volume of plasma is plotted against time for a single individual and the extent of the two dimensional region bounded by the curve and the axes of the graph is determined.
- Plasma Adiponectin Level [CMO:0000582] —
- Plasma Adrenocorticotropic Hormone Level (ACTH) [CMO:0000556] —
- Plasma Alanine Aminotransferase Activity Level [CMO:0000044] — The amount of ezymatic activity of glutamic-pyruvate transaminase enzyme, commonly known as alanine transaminase or alanine aminotransferase (ALT), enzyme in a specified sample of plasma. ALT catalyzes the reversible transamination between alanine and 2-oxoglutarate to generate pyruvate and glutamate. Plasma ALT activity level is used as an enzymatic marker for liver disease or damage.
- Plasma Albumin Level [CMO:0000056] — The amount of albumin in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Albumin to Plasma Non-albumin Protein Ratio [CMO:0002141] — A calculated measurement in which the amount of albumin in a specified sample of plasma is divided by the difference between the amount of total protein and the amount of albumin in that same sample of plasma (that is, albumin/(total protein - albumin)), and the result presented as a ratio, fraction, quotient or percentage.
- Plasma Albumin to Plasma Total Protein Ratio [CMO:0002342] — A calculated measurement in which the amount of albumin in a specified sample of plasma is divided by the total amount of protein in that same sample of plasma, and the result presented as a ratio, fraction, quotient or percentage.
- Plasma Aldosterone Level [CMO:0000551] —
- Plasma Aldosterone Level to Plasma Renin Activity Ratio [CMO:0002879] —
- Plasma Alkaline Phosphatase Activity Level [CMO:0000045] — Quantitation of the catalytic effect exerted by alkaline phosphatase (AP) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. AP is an enzyme that catalyzes the cleavage of orthophosphate from orthophosphoric monoesters under alkaline conditions.
- Plasma Alpha-fetoprotein Level [CMO:0001473] — The amount of alpha-fetoprotein, a highly abundant plasma protein produced by the yolk sac, liver and gastrointestinal tract during fetal life and by certain neoplasms in the adult, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma AMG-8718 Level [CMO:0003074] —
- Plasma AMG-8718 Level Area Under Curve (AUC) [CMO:0003076] —
- Plasma AMG-8718 Maximum Concentration [CMO:0003078] —
- Plasma Amylase Activity Leve [CMO:0003520] — The amount of enzymatic activity of amylase, a digestive enzyme that helps the body break down carbohydrates, in a specified sample of plasma. Both the salivary glands and the pancreas produce amylase. Blood amylase level is used to diagnose or monitor a problem with the pancreas.
- Plasma Androstenedione Level [CMO:0000557] —
- Plasma Angiotensin I Converting Enzyme 2 Activity Level [CMO:0002744] — Quantitation of the catalytic effect exerted by angiotensin converting enzyme2 (ACE2) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. ACE2, an ACE homolog, is a zinc-dependent peptidase of the M2-metalloprotease family that is sensitive to chloride ion concentration, and is a membrane-bound enzyme that acts as a monocarboxypeptidase and is an essential regulator of heart function.
- Plasma Angiotensin I Converting Enzyme Activity Level [CMO:0000112] — Quantitation of the catalytic effect exerted by angiotensin converting enzyme (ACE) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Angiotensin I Level [CMO:0002982] —
- Plasma Angiotensin II Level [CMO:0000572] — The amount of angiotensin II in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Angiotensin II Level to Plasma Angiotensin I Level Ratio [CMO:0002785] — A calculated measurement in which the amount of angiotensin II in a specified sample of blood plasma is divided by the amount of angiotensin I in the same or a comparable sample of blood plasma, and the result is presented as a ratio, fraction, quotient or percentage.
- Plasma Anion Gap [CMO:0000066] — The plasma anion gap is a measurement of the difference-or gap-between the negatively charged and positively charged electrolytes in plasma, i.e. blood from which cells and cellular components have been removed. If the anion gap is either too high or too low, it may be a sign of a disorder in the lungs, kidneys, or other organ systems.
- Plasma Anti-betacoronavirus Antibody Level [CMO:0003399] — Measurement of the amount of anti-betacoronavirus antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-betacoronavirus antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in a betacoronavirus. Betacoronaviruses represent one of four genera of coronaviruses of the subfamily Orthocoronavirinae in the family Coronaviridae, of the order Nidovirales.
- Plasma Anti-bovine Type 2 Collagen Antibody Level [CMO:0001273] — The amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds cattle-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-bovine Type 2 Collagen Antibody Titer [CMO:0002639] — A measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds cattle-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-collagen Antibody Level [CMO:0001271] — The amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds to one or more types of collagen, the fibrous protein constituent of bone, cartilage, tendon, and other connective tissue, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-collagen Antibody Titer [CMO:0002637] — A measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds to one or more types of collagen, the fibrous protein constituent of bone, cartilage, tendon, and other connective tissue, in a specified volume of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-coronavirus Antibody Level [CMO:0003394] — Measurement of the amount of anti-coronavirus antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-coronavirus antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in a coronavirus.
- Plasma Anti-DNA Antibody Level [CMO:0001538] — The amount of immunoglobulin molecule with an amino acid sequence that binds to deoxyribonucleic acid (DNA), a molecule composed of the sugar deoxyribose, phosphate groups and any combination of the bases adenine, guanine, cytosine, and/or thymine, in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-DNA Antibody Titer [CMO:0002634] — A measurement of the amount of immunoglobulin molecule with an amino acid sequence that binds to deoxyribonucleic acid (DNA) in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-dsDNA Antibody Level [CMO:0001537] — The amount of immunoglobulin molecule with an amino acid sequence that binds to double-stranded deoxyribonucleic acid (DNA), a molecule composed of two anti-parallel, hydrogen-bonded, polymeric strands of nucleic acids in which the sugar is deoxyribose and which is also composed of phosphate groups and any combination of the bases adenine, guanine, cytosine, and/or thymine, in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-dsDNA Antibody Titer [CMO:0002635] — A measurement of the amount of immunoglobulin molecule with an amino acid sequence that binds to double-stranded deoxyribonucleic acid (DNA), a molecule composed of two anti-parallel, hydrogen-bonded, polymeric strands of nucleic acids in which the sugar is deoxyribose and which is also composed of phosphate groups and any combination of the bases adenine, guanine, cytosine, and/or thymine, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-laminin Antibody Level [CMO:0001540] — The amount of immunoglobulin molecule with an amino acid sequence that specifically binds to laminin, a large polypeptide glycoprotein component of basement membranes, in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-laminin Antibody Titer [CMO:0002633] — A measurement of the amount of immunoglobulin molecule with an amino acid sequence that specifically binds to laminin, a large polypeptide glycoprotein component of basement membranes, in a specific sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-MERS-CoV Antibody Level [CMO:0003395] — Measurement of the amount of anti-MERS-CoV antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-MERS-CoV antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in a MERS-CoV betacoronavirus.
- Plasma Anti-porcine Type 2 Collagen Antibody Level [CMO:0001274] — The amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds pig-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-porcine Type 2 Collagen Antibody Titer [CMO:0002640] — A measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds pig-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-rat Type 2 Collagen Antibody Level [CMO:0001275] — The amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds rat-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-rat Type 2 Collagen Antibody Titer [CMO:0002642] — A measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds rat-derived type 2 collagen, the main fibrous protein constituent of cartilage, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-rat Type 2 Collagen Autoantibody Level [CMO:0002641] — The amount of an immunoglobulin molecule produced by the immune system of a rat and possessing a specific amino acid sequence that binds its own type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-rat Type 2 Collagen Autoantibody Titer [CMO:0002643] — A measurement of the amount of an immunoglobulin molecule produced by the immune system of a rat and possessing a specific amino acid sequence that binds its own type 2 collagen, the main fibrous protein constituent of cartilage, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-SARS-CoV Antibody Level [CMO:0003396] — Measurement of the amount of anti-SARS-CoV antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-SARS-CoV antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in a SARS-CoV betacoronavirus.
- Plasma Anti-SARS-CoV-2 Antibody Level [CMO:0003397] — Measurement of the amount of anti-SARS-CoV-2 antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-SARS-CoV-2 antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in a SARS-CoV-2 betacoronavirus.
- Plasma Anti-ssDNA Antibody Level [CMO:0001536] — The amount of immunoglobulin molecule with an amino acid sequence that binds to single-stranded deoxyribonucleic acid (DNA), a single polymeric strand of nucleic acids in which the sugar is deoxyribose and which is also composed of phosphate groups and any combination of the bases adenine, guanine, cytosine, and/or thymine, in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-ssDNA Antibody Titer [CMO:0002636] — A measurement of the amount of immunoglobulin molecule with an amino acid sequence that binds to single-stranded deoxyribonucleic acid (DNA), a single polymeric strand of nucleic acids in which the sugar is deoxyribose and which is also composed of phosphate groups and any combination of the bases adenine, guanine, cytosine, and/or thymine, in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Anti-toxoplasma Antibody Level [CMO:0001829] — Measurement of the amount of anti-toxoplasma antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. An anti-toxoplasma antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in the parasite toxoplasma, a genus of sporozoa the only species of which is Toxoplasma gondii that are intracellular parasites of many organs and tissues of birds and mammals, including humans. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host. An antigen is a substance introduced into an organism which initiates an immune response, including the production of the very antibodies which bind to it in an effort to destroy it.
- Plasma Anti-toxoplasma Antibody Titer [CMO:0002030] — The amount of anti-toxoplasma antibodies in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended, expressed as the last dilution of plasma at which a positive result could be obtained. An anti-toxoplasma antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen found on or in the parasite toxoplasma, a genus of sporozoa the only species of which is Toxoplasma gondii that are intracellular parasites of many organs and tissues of birds and mammals, including humans. A parasite is an organism that grows, feeds, and is sheltered on or in a different organism while contributing nothing to the survival of its host and possibly causing damage to that host. An antigen is a substance introduced into an organism which initiates an immune response, including the production of the very antibodies which bind to it in an effort to destroy it.
- Plasma Anti-type 2 Collagen Antibody Level [CMO:0001272] — The amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Anti-type 2 Collagen Antibody Titer [CMO:0002638] — Measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds type 2 collagen, the main fibrous protein constituent of cartilage, in a specified volume of serum,expressed as the last dilution of serum at which a positive result could be obtained.
- Plasma Antibody Level [CMO:0000478] — A measurement of the amount of an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen, a substance introduced into an organism which initiates an immune response including the production of the very antibodies which bind to it in an effort to destroy it, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Antibody Titer [CMO:0002618] — A measurement of the amount of a specific antibody in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained. Plasma is the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Apolipoprotein Level [CMO:0000120] — The amount of proteins that bind to lipids found in a specific volume of plasma.
- Plasma Arginine Level [CMO:0003734] — Measurement of the amount of arginine, an alpha-amino acid that is glycine in which the side chain (R group) is a 3-guanidinopropyl group, in blood plasma.
- Plasma Arginine Level to Asymmetric Dimethylarginine Level Ratio [CMO:0003739] — A calculated measurement in which the value for the amount of arginine in a specified sample of plasma is divided by the value for the level of asymmetric dimethylarginine in the same sample of plasma, and the result is presented as a ratio, fraction, quotient or percentage.
- Plasma Aspartate Aminotransferase Activity Level [CMO:0000043] — The amount of enzymatic activity of glutamic-oxaloacetic transaminase enzyme, commonly known as aspartate transaminase or aspartate aminotransferase (AST), in a specified sample of plasma. AST catalyzes the reversible transfer of an amine group from l-glutamic acid to oxaloacetic acid, forming alpha-ketoglutaric acid and l-aspartic acid. Plasma AST level is used as an enzymatic marker for liver disease or damage.
- Plasma Asymmetric Dimethylarginine Level [CMO:0003735] — Measurement of the amount of asymmetric dimethylarginine, an arginine derivative that is arginine substituted by two methyl groups, in blood plasma.
- Plasma Autoantibody Level [CMO:0002108] — Measurement of the amount of one or more autoantibodies in a specified sample of plasma. An antibody is an immunoglobulin molecule possessing a specific amino acid sequence that binds to a specific antigen, a substance introduced into an organism which initiates an immune response including the production of the very antibodies which bind to it in an effort to destroy it. An autoantibody is an antibody that attacks the cells, tissues, native proteins, or other endogenous molecules of the organism in which it was formed.
- Plasma Autoantibody Titer [CMO:0002615] — Measurement of the amount of one or more autoantibodies in a specified sample of plasma, expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Bicarbonate Level [CMO:0000062] — The amount of carbonic acid dissolved in carbon dioxide and bicarbonate ion found in a specific volume of plasma.
- Plasma Bradykinin Level [CMO:0003207] —
- Plasma C-reactive Protein Level [CMO:0003162] — The proportion, quantity, or volume of C-reactive protein (CRP) found in the plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. CRP is an acute phase reactant protein used to indicate inflammatory illness. It is believed to be of value in predicting coronary events.
- Plasma Calcium Level [CMO:0000065] — The amount of calcium found in a specific volume of plasma.
- Plasma Campesterol Level [CMO:0001944] — The amount of campesterol, a phytosterol (molecular formula C28H48O) whose chemical structure is similar to that of cholesterol, in a specified sample of plasma.
- Plasma Carboxyhemoglobin Level [CMO:0000589] — A measure of the amount of carboxyhemoglobin formed by the combination of carbon monoxide and hemoglobin in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Cartilage Oligomeric Matrix Protein Level [CMO:0001958] — The amount of cartilage oligomeric matrix protein (COMP), a noncollagenous extracellular matrix protein that serves as a marker of cartilage turnover, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Ceruloplasmin Level [CMO:0003467] — The amount of ceruloplasmin in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Chloride Level [CMO:0000059] — The amount of chloride ions found in a specific volume of plasma.
- Plasma Cholesterol Level [CMO:0002282] — The amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Cholesterol in the plasma is associated with various lipoproteins.
- Plasma Chylomicron and VLDL Cholesterol Level [CMO:0003901] — This is a calculated measurement in which the value for chylomicron cholesterol and the value for very low density lipoprotein cholesterol in a specified sample of plasma are added together for an approximation of non-HDL, non-LDL cholesterol in that same sample.
- Plasma Chylomicron Cholesterol Level [CMO:0002684] — Measurement of the amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, carried in chylomicron molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Chylomicrons are a class of lipoproteins (approximate density range <0.95 g/ml) that transport exogenous triglycerides and cholesterol from the small intestine to other tissues.
- Plasma Chylomicron Level [CMO:0001577] — Measurement of the amount of chylomicrons, a class of lipoproteins (approximate density range <0.95 g/ml) that transport exogenous triglycerides and cholesterol from the small intestine to other tissues, found in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Complement C3a Des Arg Level [CMO:0003696] — This is a measurement of the amount of C3a des Arg in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. C3a des Arg is formed from C3a via carboxypeptidase cleavage of the C-terminal arginine group.
- Plasma Copper Level [CMO:0003464] — The amount of copper, an essential dietary trace element, atomic number 29, involved in the formation of bone and blood as a necessary component of several enzymes, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Corticosterone Level [CMO:0001173] — The amount of corticosterone, a corticosteroid produced in the adrenal cortex that functions in the metabolism of carbohydrates and proteins, found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Corticosterone Level to 11-dehydrocorticosterone Level Ratio [CMO:0003514] — A calculated measurement in which the amount of corticosterone in a sample of plasma is divided by the amount of 11-dehydrocorticosterone in that sample and presented as a ratio, fraction, quotient or percentage, thus normalizing it to the 11-dehydrocorticosterone level.
- Plasma Cortisol Level [CMO:0000554] —
- Plasma Creatine Kinase Activity Level [CMO:0002243] — The amount of enzymatic activity of creatine kinase (CK) enzyme in a specified sample of plasma. CK catalyses the reversible transfer of phosphate between ATP and various phosphogens such as creatine phosphate. Plasma CK level is used as an enzymatic marker for myocardial infarction, rhabdomyolysis and acute renal failure.
- Plasma Creatinine Level [CMO:0000537] —
- Plasma Cystatin C Level [CMO:0002778] — The amount of the protein cystatin C found in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Dehydroepiandrosterone Level [CMO:0000559] —
- Plasma Dihydrotestosterone Level [CMO:0000561] —
- Plasma Dipeptidyl Peptidase 4 Activity Level [CMO:0003011] —
- Plasma Direct Bilirubin Level [CMO:0000048] — The level of direct bilirubin in a specified sample of blood plasma. Direct bilirubin is produced when the unconjugated form is carried to the liver where it is conjugated to form the water-soluble bilirubin diglucuronide.
- Plasma Direct Renin Activity Level [CMO:0002500] — Measurement of the amount of renin activity in a specified sample of plasma (the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended) via the direct immunologic detection of the renin protein in the sample and subsequent conversion of the protein level to an activity level.
- Plasma Dopamine Level [CMO:0001784] — Measurement of the amount of dopamine, a catecholamine hormone and neurotransmitter formed by the decarboxylation of dopa, which is an intermediate product in the synthesis of norepinephrine and is involved motor control, cognition, and reward, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma E. Coli Specific Antibody Level [CMO:0000479] — The amount of immunoglobulin molecule with an amino acid sequence that binds with Escherichia coli, a Gram negative rod-shaped bacterium, in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma E. Coli Specific Antibody Level Change, Post Challenge [CMO:0000483] — The difference in the amount of immunoglobulin molecule with sequence that binds to Eschericia coli, a Gram negative rod-shaped bacteria in specified volumes of plasma taken before a directed E. coli exposure and at a determined time point after E. coli challenge.
- Plasma E. Coli Specific Antibody Level Change, Post Vaccination [CMO:0000482] — The difference in the amount of immunoglobulin molecule with sequence that binds to Escherichia coli, a Gram negative rod-shaped bacteria, in specified volumes of plasma taken before vaccination and at a determined time point after vaccination.
- Plasma E. Coli Specific Antibody Level, Post Challenge [CMO:0000480] — The amount of immunoglobulin molecule with a sequence that binds to Escherichia coli, a Gram negative rod-shaped bacteria, in a specific volume of plasma taken at a determined time point following a directed exposure to E. coli.
- Plasma E. Coli Specific Antibody Level, Post Vaccination [CMO:0000481] — The amount of an immunoglobulin with a sequence that binds to Escherichia coli, a Gram negative rod-shaped bacteria, in a specific volume of plasma taken at a determined time point following vaccination for E. coli.
- Plasma E. Coli Specific Antibody Titer [CMO:0002604] — The amount of immunoglobulin molecule with an amino acid sequence that binds with Escherichia coli, a Gram negative rod-shaped bacterium, in a specific volume of plasma expressed as the last dilution of plasma at which a positive result could be obtained.
- Plasma Eicosanoid Level [CMO:0003407] — Measurement of the amount of one or more eicosanoids, physiologically active molecules derived by oxidation of twenty-carbon essential fatty acids such as arachidonic acid, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Epinephrine Level [CMO:0001008] — The amount of epinephrine, a catecholamine which can act as a neurotransmitter, a stress hormone, a stimulator of the sympathetic nervous system and a vasoconstrictor, found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Estradiol Level [CMO:0000563] —
- Plasma Ethanol Level [CMO:0000570] — The amount of ethanol, the colorless, volatile, flammable liquid, CH3CH2OH, produced by yeast fermentation of carbohydrates or synthesized by hydration of ethylene, found in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Free Fatty Acids Level [CMO:0000546] — The amount of free fatty acids found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Fructosamine Level [CMO:0002857] —
- Plasma Gamma-glutamyltransferase Activity Level [CMO:0002240] — The amount of enzymatic activity of gamma-glutamyltransferase (GGT) in a specified sample of plasma. GGT catalyzes the transfer of the gamma-glutamyl moiety of glutathione to an acceptor such as amino acid, a peptide or water. Plasma GGT level is used as an enzymatic marker for liver disease or damage.
- Plasma Gastric Inhibitory Polypeptide Level [CMO:0003641] — The amount of gastric inhibitory polypeptide, a 42-amino-acid hormone that is produced by enteroendocrine K-cells and released into the circulation in response to nutrient stimulation, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Globulin Level [CMO:0002401] — Measurement of the amount of globulins, a broad category of plasma proteins, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Glucagon Level [CMO:0001296] — The amount of glucagon, a peptide secreted by pancreatic alpha cells which plays an important role in regulation of blood glucose concentration, ketone metabolism, and other biochemical and physiological processes, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Glucagon-like Peptide 1 Level [CMO:0003638] — The amount of glucagon-like peptide 1, a peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
- Plasma Glucose Level [CMO:0000042] — Measurement of the amount of glucose, the monosaccharide sugar, C6H12O6, occurring widely in plant and animal tissues which is one of the three dietary monosaccharides that are absorbed directly into the bloodstream during digestion, is the end product of carbohydrate metabolism, and is the chief source of energy for living organisms, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Glutamate Dehydrogenase Activity Level [CMO:0002476] — Measurement of the amount of ezymatic activity of glutamate dehydrogenase, the enzyme which catalyzes the interconversion of glutamate and alpha-ketoglutarate (ie, the reversible conversion of glutamic acid to 2-oxoglutaric acid and ammonia), in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Glutathione Level [CMO:0002434] — The amount of glutathione in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Glutathione (GSH) is an antioxidant tripeptide with a gamma peptide linkage between the amine group of cysteine (which is attached by normal peptide linkage to a glycine) and the carboxyl group of the glutamate side-chain.
- Plasma Glutathione Peroxidase Activity Level [CMO:0002443] — The amount of ezymatic activity of glutathione peroxidase in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Glutathione peroxidase (GPx) is an enzyme that catalyzes the reaction of two glutathiones with H2O2, forming glutathione disulfide and two water molecules, and is a crucial enzyme in hydrogen peroxide detoxification.
- Plasma Glycerol Level [CMO:0002681] — The amount of free glycerol, a trihydroxy sugar alcohol produced by lipolysis of triglycerides in adipose tissue and a precursor for the synthesis of triacylglycerols and phospholipids in the body, found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Growth Hormone Level [CMO:0001228] — Measurement of the amount of growth hormone, a polypeptide hormone which promotes body growth and fat mobilization and inhibits glucose utilization, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Haptoglobin Level [CMO:0002521] — Measurement of the amount of haptoglobin in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Haptoglobin is a serum alpha2 globulin glycoprotein, produced by the liver, that functions to bind free plasma hemoglobin, which allows degradative enzymes to gain access to the hemoglobin, while at the same time preventing loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin.
- Plasma Hemoglobin Level [CMO:0000588] — The amount of hemoglobin, the oxygen carrying pigment of erythrocytes, found in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Hesperetin Level [CMO:0003004] — The amount of hesperetin found in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.Hesperetin, in the form of its glycoside Hesperidin, is the predominant flavonoid in lemons and oranges.
- Plasma High Density Lipoprotein Cholesterol Level [CMO:0000646] — Measurement of the amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, carried in high-density lipoprotein (HDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. HDL is the smallest of the major lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The HDL class of lipoproteins, specifically the subtypes of HDL2 and HDL3, have densities between 1.063 and 1.210 g/ml.
- Plasma High Density Lipoprotein Phospholipid Level [CMO:0001566] — Measurement of the amount of phospholipid, any of various phosphorus-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule such as glycerol, carried in high-density lipoprotein (HDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. HDL is the smallest of the major lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The HDL class of lipoproteins, specifically the subtypes of HDL2 and HDL3, have densities between 1.063 and 1.210 g/ml.
- Plasma IDL and LDL Cholesterol [CMO:0003903] — This is a calculated measurement in which the value for intermediate density lipoprotein (IDL) cholesterol and the value for low density lipoprotein (LDL) cholesterol in a specified sample of plasma are added together for an approximation of non-HDL, non-chylomicron/VLDL cholesterol in that same sample. Together, IDL and LDL cover a plasma density of 1.006 to 1.063 g/ml.
- Plasma Immunoglobulin A Level [CMO:0002096] — The amount in a specified sample of plasma of one or more types of immunoglobulin A (IgA), one of the most prevalent of the five classes of antibodies produced by the body. IgA is found in all secretions of the body and is the major antibody in the tears, saliva, and mucous membranes lining the intestines and bronchi, constituting an important factor in mucosal immunity.
- Plasma Immunoglobulin D Level [CMO:0002098] — The amount in a specified sample of plasma of one or more types of immunoglobulin D (IgD), one of the five classes of antibodies produced by the body. IgD is found in small amounts in serum, and although its precise function is not known, IgD increases in quantity during allergic reactions to milk, insulin, penicillin, and various toxins.
- Plasma Immunoglobulin E Level [CMO:0002100] — The amount in a specified sample of plasma of one or more types of immunoglobulin E (IgE), one of the five classes of antibodies produced by the body which is concentrated in the lungs, skin, and mucous membranes and, as a primary defense against environmental antigens, can trigger anaphylactic hypersensitivity.
- Plasma Immunoglobulin G Level [CMO:0002103] — The amount in a specified sample of plasma of one or more types of immunoglobulin G (IgG), the most abundant class of antibodies found in blood serum and lymph. IgG antibodies are active against bacteria, fungi, viruses, and foreign particles, and trigger action of the complement system.
- Plasma Immunoglobulin M Level [CMO:0002105] — The amount in a specified sample of plasma of one or more types of immunoglobulin M (IgM), one of the five classes of antibodies produced by the body. IgM is found in circulating body fluids and is the first class of antibodies to appear in response to an initial exposure to an antigen.
- Plasma Immunoglobulin Measurement [CMO:0000477] — Any measurement related to immunoglobulin, any of several classes of proteins produced by plasma cells and lymphocytes which play essential roles in the immune system, for example, attaching to foreign substances in an effort to destroy them, in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Indirect Bilirubin Level [CMO:0000047] — The amount of indirect or unconjugated bilirubin in a specified sample of blood plasma. Indirect bilirubin is the lipid-soluble form of bilirubin that circulates in loose association with the plasma proteins. It can be calculated by subtracting direct bilirubin level from the total bilirubin level.
- Plasma Insulin Level [CMO:0000342] — The amount of insulin, the fuel-regulating peptide hormone which is formed from proinsulin in the beta cells of the pancreatic islets and which promotes the storage of glucose and the uptake of amino acids, increases protein and lipid synthesis, and inhibits lipolysis and gluconeogenesis, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Insulin Level to Plasma Glucose Level Ratio [CMO:0003555] — A calculated measurement in which the value for the amount of insulin in a specified sample of plasma is divided by the value for the level of glucose in the same sample of plasma, and the result is presented as a ratio, fraction, quotient or percentage.
- Plasma Insulin-like Growth Factor 1 Level [CMO:0001299] — The amount of insulin-like growth factor 1, a basic peptide with growth-regulating, insulin-like, and mitogenic activities which is largely dependent on growth hormone, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Insulin-like Growth Factor 2 Level [CMO:0001301] — The amount of insulin-like growth factor 1, a neutral peptide with growth-regulating, insulin-like, and mitogenic activities which is largely dependent on somatotropin, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Interleukin-6 Level [CMO:0001927] — Measurement of the amount of interleukin-6 (IL6) in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. IL6 is an interleukin that acts as both a pro-inflammatory and an anti-inflammatory cytokine with functions in inflammation and the maturation of B cells.
- Plasma Intermediate Density Lipoprotein Cholesterol Level [CMO:0001563] — This is a measurement of the amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, carried in intermediate-density lipoprotein (IDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. IDL are relatively large lipoprotein particles (complexes that consist of protein surrounding a core of lipids) formed by degradation of very low density lipoproteins (VLDL) particles and thus having a size intermediate between those of VLDL and low density lipoproteins. The IDL class of lipoproteins is defined as having a density between 1.006 and 1.019 g/ml.
- Plasma Intermediate Density Lipoprotein Phospholipid Level [CMO:0001575] — Measurement of the amount of phospholipid, any of various phosphorus-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule such as glycerol, carried in intermediate-density lipoprotein (IDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. IDL are relatively large lipoprotein particles (complex molecules that consist of a protein membrane surrounding a core of lipids) formed by degredation of very low density lipoproteins (VLDL) particles and thus having a size intermediate between those of VLDL and low density lipoproteins. The IDL class of lipoproteins is defined as having a density between 1.006 and 1.019 g/ml.
- Plasma Ionized Calcium Level [CMO:0000377] — The level of calcium ions in a specified volume of plasma.
- Plasma Lactate Dehydrogenase Activity Level [CMO:0000667] — The amount of ezymatic activity of lactate dehydrogenase (LDH) in a specified volume of plasma. LDH is the enzyme which catalyses the reaction S)-lactate + NAD(+) <=> pyruvate + NADH. Plasma LDH level can be used as a marker for tissue damage.
- Plasma Lactate Level [CMO:0001305] — The amount of lactate, a salt of lactic acid which is produced in the body by anaerobic metabolism of carbohydrate, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Leptin Level [CMO:0000781] —
- Plasma Lipase Activity Level [CMO:0003755] — Any quantitation of the catalytic effect exerted by lipase in a specified sample of blood plasma. Lipase, is an enzyme that catalyzes the hydrolysis of lipids. It's normal to have a small amount of lipase in blood, but a high level of lipase can mean the subject has some type of pancreatic disease.
- Plasma Lipid Level [CMO:0000544] —
- Plasma Low Density Lipoprotein Cholesterol Level [CMO:0000647] — Measurement of the amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, carried in low-density lipoprotein (LDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. LDL constitute a class of relatively large, heterogeneous lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The LDL class of lipoproteins has a density between 1.019 and 1.063 g/ml. In some animal species, such as canine and rodents, this may overlap with the HDL1 class and be designated LDL/HDL1.
- Plasma Low Density Lipoprotein Phospholipid Level [CMO:0001569] — Measurement of the amount of phospholipid, any of various phosphorus-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule such as glycerol, carried in low-density lipoprotein (LDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. LDL constitute a class of relatively large, heterogeneous lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The LDL class of lipoproteins has a density between 1.019 and 1.063 g/ml. In some animal species, such as canine and rodents, this may overlap with the HDL1 class and be designated LDL/HDL1.
- Plasma Magnesium Level [CMO:0000217] — The amount of magnesium ions in a specified volume of plasma.
- Plasma Malondialdehyde Level [CMO:0002448] — The amount of malondialdehyde in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Malondialdehyde is an organic compound with the formula CH2(CHO)2. It is a reactive species which occurs naturally, is generally found in the enol form (HOCH=CH-CHO), and is a marker for oxidative stress. Malondialdehyde is the substrate for the TBARS (thiobarbituric acid reactive substances) assay of lipid peroxidation.
- Plasma Murinoglobulin 1 Level [CMO:0001931] — Measurement of the amount of murinoglobulin 1 (MUG1) in plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. MUG1 is a putative protease inhibitor related to alpha-2-macroglobulin and involved in the acute phase inflammatory response.
- Plasma NAG Activity Level [CMO:0003486] — The amount of enzymatic activity of N-acetyl-β-d-glucosaminidase (NAG) in a specified sample of plasma. N-Acetyl-β-D-Glucosaminidase (NAG) is an intracellular lysosomal enzyme, present in the S3 segment of proximal tubular cells and distal nephron.
- Plasma NH2-terminal Pro-B-type Natriuretic Peptide Level [CMO:0002877] —
- Plasma Nifedipine Clearance [CMO:0003140] — The measurement of the rate at which nifedipine is eliminated from blood plasma.
- Plasma Nifedipine Level [CMO:0003136] — This is a measure of the content of this potent vasodilator agent in blood plasma.
- Plasma Nifedipine Level Area Under Curve [CMO:0003138] — A calculated measurement in which a series of measurements of the amount of nifedipine in a specified volume of plasma is plotted against time for a single individual and the extent of the two dimensional region bounded by the curve and the axes of the graph is determined.
- Plasma Non-HDL, Non-LDL Cholesterol Level [CMO:0002283] — A calculated measurement in which the value for high density lipoprotein cholesterol and the value for low density lipoprotein cholesterol in a specified sample of plasma are subtracted from the value for total cholesterol in that same sample. For rodents, the result is an approximation of the amount of very low density lipoprotein cholesterol in that sample.
- Plasma Norepinephrine Level [CMO:0001010] — The amount of norepinephrine, a catecholamine which can act as a neurotransmitter, a stress hormone and a vasoconstrictor, found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Orosomucoid 1 Level [CMO:0001467] — The amount of the acute-phase reactant orosomucoid 1 (ORM1; alpha-1-acid glycoprotein), a member of the lipocalin protein family which is upregulated during inflammation, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Osmolality [CMO:0002923] — The number of dissolved particles in a specified volume of plasma.
- Plasma Osteocalcin Level [CMO:0002823] —
- Plasma Oxidized Glutathione Level [CMO:0002436] — The amount of oxidized glutathione (GSSG) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. GSSG is a molecule produced when glutathione is used as a reducing agent in a biochemical reaction, and consists of a pair of glutathione molecules connected by a disulfide bridge between their cysteine residues.
- Plasma Parathyroid Hormone Level [CMO:0002962] —
- Plasma Phosphate Level [CMO:0000058] — The amount of phosphorus, measured as inorganic phosphate, in a specified sample of plasma.
- Plasma Phospholipid Level [CMO:0001170] — Measurement of the amount of any of various phosphorus-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Phytosterol Level [CMO:0001945] — The amount of phytosterol(s) in a specified sample of plasma. Phytosterols, which encompass both plant sterols and stanols, comprise a large group of steroid compounds similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.
- Plasma Plasminogen Activator Inhibitor 1 Level [CMO:0003695] — Measurement of the amount of plasminogen activator inhibitor 1 (PAI-1) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. PAI-1 is a serine protease inhibitor protein that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and hence fibrinolysis (the physiological breakdown of blood clots).
- Plasma Potassium Level [CMO:0000061] — The amount of potassium ions found in a specific volume of plasma.
- Plasma ProANF 31-67 Peptide Level [CMO:0003507] — This is a measurement of the amount of proANF 31-67 (a.a 31-67 of the amino terminal of pro hormone ANP (Nppa)) in a specified volume of plasma.
- Plasma Progesterone Level [CMO:0000565] —
- Plasma Prolactin Level [CMO:0001824] — The amount of prolactin found in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Prolactin is a peptide hormone which is secreted by the anterior pituitary and is involved in lactation, growth regulation for tissues including cells of the immune system, and possibly supression of apoptosis. A peptide hormone is a complex organic compound that contains carbon, hydrogen, oxygen, nitrogen, and sulfur consisting of alpha-amino acids joined by peptide linkages, and that is produced in one part or organ of the body and initiates or regulates the activity of an organ or a group of cells in another part of the body.
- Plasma Pyrophosphate Level [CMO:0003228] — This is a measure of pyrophosphates in plasma, the clear liquid that separates from blood after the cells and platelets have been removed. Pyrophosphates are phosphorus oxyanions that contain two phosphorus atoms in a P-O-P linkage with the formula O7P2.
- Plasma Pyruvate Level [CMO:0002424] — The amount of pyruvate in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Reduced Glutathione Level [CMO:0002440] — The amount of reduced glutathione (GSH) in a specified sample of plasma. GSH is an antioxidant tripeptide with a gamma peptide linkage between the amine group of cysteine (which is attached by normal peptide linkage to a glycine) and the carboxyl group of the glutamate side-chain. In GSH (as opposed to the oxidized form, GSSG) the thiol group on the cysteine is in its reduced form, that is, it contains a hydrogen atom and does not form a disulfide bridge with a second glutathione molecule.
- Plasma Renin Activity Level [CMO:0000116] — An estimation of the amount of renin in a specific volume of plasma calculated from the rate of formation of angiotensin I or II.
- Plasma Retinol Level [CMO:0002456] — The amount of retinol in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Retinol is a 20-carbon primary alcohol in any of several isomers that is the form of vitamin A found in mammals and that can be converted to the metabolically active forms retinal and retinoic acid.
- Plasma Sitosterol Level [CMO:0001943] — The amount of sitosterol, a phytosterol (molecular formula C29H50O) with chemical structures similar to that of cholesterol, in a specified sample of plasma.
- Plasma Sodium Level [CMO:0000060] — The amount of sodium ions found in a specific volume of plasma.
- Plasma Sorbital Dehydrogenase Activity [CMO:0003278] — Quantitation of the catalytic effect exerted by Sorbitol dehydrogenase in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Sorbitol dehydrogenase is an enzyme in carbohydrate metabolism converting sorbitol, the sugar alcohol form of glucose, into fructose.
- Plasma Sterol Level [CMO:0002050] — The amount of sterol, any of a group of steroids with a long (8 to 10 carbons) aliphatic side-chain at position 17 and at least one alcoholic group, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Superoxide Dismutase Activity Level [CMO:0002446] — The amount of ezymatic activity of superoxide dismutase (SOD) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. SOD is a metalloprotein enzyme that catalyses the conversion of highly reactive superoxide radicals (O2-) to the less toxic products hydrogen peroxide (H2O2) and molecular oxygen (O2).
- Plasma Symmetric Dimethylarginine Level [CMO:0003736] — Measurement of the amount of symmetric dimethylarginine, an arginine derivative that is arginine substituted by two methyl groups, in blood plasma.
- Plasma Testosterone Level [CMO:0000567] —
- Plasma Thyroid Stimulating Hormone Level [CMO:0001249] — Measurement of the amount of thyroid-stimulating hormone, a glycoprotein hormone secreted by the anterior lobe of the pituitary gland that stimulates and regulates activity of the thyroid gland, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Thyroxine Level [CMO:0001289] — The amount of thyroxine, the major hormone derived from the thyroid gland which regulates cellular metabolism, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Total Bilirubin Level [CMO:0002334] — The complete or entire amount of bilirubin in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Bilirubin is the bile pigment produced by breakdown of heme and reduction of biliverdin.
- Plasma Total Cholesterol Level [CMO:0000585] — Measurement of the entire amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, without taking into account any association with other molecules such as lipoproteins, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Total Immunoglobulin E Level [CMO:0001541] — The total amount of immunoglobulin E (IgE), one of the five classes of antibodies produced by the body which is concentrated in the lungs, skin, and mucous membranes and, as a primary defense against environmental antigens, can trigger anaphylactic hypersensitivity, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Total Protein Level [CMO:0000054] — Measurement of the total amount of all proteins, the complex organic compounds containing carbon, hydrogen, oxygen, nitrogen, and sulfur consisting of alpha-amino acids joined by peptide linkages, found in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Triglyceride Level [CMO:0000548] — The amount of triglycerides in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Triglycerides are any of a group of lipids that are esters formed from one molecule of glycerol and three molecules of one or more fatty acids, are widespread in adipose tissue, and commonly circulate in the blood in the form of lipoproteins.
- Plasma Triglyceride Level Area Under Curve [CMO:0003608] — A calculated measurement in which a series of measurements of the amount of triglycerides in a specified volume of plasma is plotted against time for a single individual and the extent of the two dimensional region bounded by the curve and the axes of the graph is determined.
- Plasma Triiodothyronine Level [CMO:0001292] — The amount of triiodothyronine, a hormone synthesized and secreted by the thyroid which constitutes the main thyroid hormone used by the tissues, in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Troponin T Level [CMO:0001286] — The amount of troponin T, one subunit of a complex of three regulatory proteins required for skeletal and cardiac muscle contraction in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Type I Collagen C-terminal Telopeptide Level [CMO:0002819] — The amount of type I collagen C-terminal telopeptide in a specified volume of plasma. The C-terminal telopeptide can be used as a biomarker in the serum to measure the rate of bone turnover.
- Plasma Tyrosinase Activity Level [CMO:0002531] — Quantitation of the catalytic effect exerted by tyrosinase (Tyr) in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. Tyr is a copper-containing enzyme of plant and animal tissues that catalyzes the production of melanin and other pigments from tyrosine by oxidation. Tyr is the rate-limiting enzyme for controlling the production of melanin.
- Plasma Urea Level [CMO:0003878] — This is the level of urea in blood plasma, i.e. blood from which cells and cellular components have been removed. This value can be determined by converting urea nitrogen to urea concentration by multiplying urea nitrogen concentration by 60/28 or 2.14. Urea is the chief nitrogenous end product of protein metabolism in whole blood. Urea is formed in the liver from amino acids and from ammonia compounds and can be found in urine, blood, and lymph.
- Plasma Urea Nitrogen Level [CMO:0000586] — The level of urea in terms of nitrogen content measured in a specific volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.The plasma urea nitrogen level is converted to urea concentration by multiplying by 60/28 or 2.14. Urea is the chief nitrogenous end product of protein metabolism in whole blood. Urea is formed in the liver from amino acids and from ammonia compounds and can be found in urine, blood, and lymph.
- Plasma Uric Acid Level [CMO:0002042] — The amount of uric acid, a heterocyclic compound of carbon, nitrogen, oxygen, and hydrogen,the end product of purine catabolism, in a specified sample of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended.
- Plasma Urotensin II Level [CMO:0003214] —
- Plasma Vasopressin Level [CMO:0002905] —
- Plasma Very Low Density Lipoprotein Cholesterol Level [CMO:0000649] — Measurement of the amount of cholesterol, a eukaryotic sterol that in higher animals is the precursor of bile acids and steroid hormones and a key constituent of cell membranes, carried in very low-density lipoprotein (VLDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. VLDL constitute a class of large (e.g. approximately 30-80 nm in diameter) lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The VLDL class of lipoproteins has a density between 0.95 and 1.006 g/ml.
- Plasma Very Low Density Lipoprotein Phospholipid Level [CMO:0001572] — Measurement of the amount of phospholipid, any of various phosphorus-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule such as glycerol, carried in very low-density lipoprotein (VLDL) molecules in a specified volume of plasma, the fibrinogen-containing fluid portion of the blood in which the particulate components are suspended. VLDL constitute a class of large (e.g. approximately 30-80 nm in diameter) lipoprotein particles, complex molecules that consist of a protein membrane surrounding a core of lipids. The VLDL class of lipoproteins has a density between 0.95 and 1.006 g/ml.
- Platelet Aggregation Measurement [CMO:0000920] — Measurement of the ability of platelets to aggregate in response to a known platelet aggregating factor such as collagen, ADP or thrombin.
- Platelet Count [CMO:0000029] — The number of platelets (thrombocytes) in a specified volume of blood, usually expressed as platelets per cubic millimeter of whole blood.
- Platelet Distribution Width [CMO:0001350] — A measurement of platelet anisocytosis calculated from the distribution of individual platelet volumes.
- Platelet Distribution Width (percentage) [CMO:0003526] — A measurement of platelet anisocytosis calculated from the distribution of individual platelet volumes and reported as percentage.
- Platelet Function Measurement [CMO:0000923] — Any measurement which is used to assess the ability of platelets to become activated, aggregate and promote clotting.
- Platelet Intracellular Calcium Level [CMO:0000922] — Measurement of the amount or concentration of calcium within platelets.
- Platelet Measurement [CMO:0000921] — Any measurement of platelets, the disk-shaped structures found in the blood of mammals which play a vital role in blood coagulation. Platelets lack nuclei and DNA but contain active enzymes and mitochondria.
- Platelet Morphological Measurement [CMO:0003100] —
- Platelet Physiological Measurement [CMO:0003101] —
- Platelet-large Cell Ratio [CMO:0003233] — Platelet-large cell ratio (P-LCR) is defined as the ratio of platelets that exceed the normal value of platelet volume (e.g. 12 fL in human) to the total platelet count.
- Plateletcrit [CMO:0001349] — The proportion of blood volume that is occupied by platelets, expressed as a percentage.
- Pleura Ribonucleic Acid Composition Measurement [CMO:0003345] —
- Podocyte Foot Process Height [CMO:0003715] — This is an average value of the distance between the basal side of the podocyte contacting the basement membrane and the apical side of the podocyte projecting into the urinary space. The value is derived from the measurements of podocytes during computerized analysis of electron micrographs.
- Podocyte Foot Process Width [CMO:0003714] — This is a calculated value estimated from the measurement of foot processes and an equation adjusting for ambiguity of electron microscopic images of podocyte foot process boundaries.
- Podocyte Slit Width [CMO:0003713] — This is an average value for the gap distance between interdigitating foot processes of podocytes in kidney glomeruli. The value is derived from the measurements of podocytes during computerized analysis of electron micrographs.
- Pons Ribonucleic Acid Composition Measurement [CMO:0003366] —
- Poorly Differentiated Malignant Colorectal Tumor Number [CMO:0002076] — A value or quantity determined by count of poorly differentiated malignant colorectal tumors, abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and do not display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Poorly Differentiated Malignant Colorectal Tumor Surface Area Measurement [CMO:0002078] — A measurement of the two-dimensional extent of a planar region comprising the superficial or external aspect of one or more poorly differentiated malignant colorectal tumors, abnormal growths of tissue in the large intestine resulting from uncontrolled, progressive multiplication of cells and serving no physiological function, which display the properties of anaplasia, invasiveness and metastasis, and do not display specific physical forms, physiologic functions, and chemical properties characteristic of the tissue.
- Post Excision/regeneration Liver Volume to Original Liver Volume Ratio [CMO:0003760] — A calculated measurement in which the size of the three dimensional space (volume) occupied by one or more lobes of the liver after excision and subsequent regeneration is divided by the original, preoperative volume and presented as a ratio, fraction, quotient or percentage.
- Post Insult Time to Regain Baseline Tilted Plane Angle at Loss of Balance/traction [CMO:0002295] — Measurement of the length of time between introduction of a stimulus or effector and the timepoint at which the angle of inclination, i.e., the degree of divergence from the horizontal, of a surface at the moment when a subject sitting or standing on that surface can no longer maintain its balance or remain in a stable position, is the same as the value of that angle before the introduction of the stimulus or effector.
- Post-insult Time of Death [CMO:0002005] — Measurement of the length of time between introduction of a disease-producing or otherwise toxic stimulus and the death of the subject, i.e. the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
- Post-insult Time of Death Due to ENU-induced Malignant Peripheral Nerve Sheath Tumors [CMO:0003874] — This is a measurement of the length of time between an injection of N-ethyl-N-nitrosourea (ENU) and the death of the subject as a result of malignant peripheral nerve sheath tumors.
- Post-insult Time of Death Due to Metastatic Liver Tumors [CMO:0003882] — This is a measurement of the length of time between experimental introduction of metastatic liver tumors and the death of the subject, i.e. the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
- Post-insult Time of Death from IgM Immunocytoma [CMO:0003836] — This is a measurement of the length of time between introduction of an IgM immunocytoma and the death of the subject, i.e. the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
- Post-insult Time to Mammary Tumor Formation [CMO:0000345] — The amount of time to the first discernible appearance of tumor in the mammary gland following the administration of a tumor causing agent.
- Post-insult Time to Onset of Cerebrovascular Lesion [CMO:0002343] — Measurement of the length of time between introduction of a lesion-producing stimulus, sucn as a trauma or a drug, and the observation of symptoms of cerebrovascular lesion or stroke.
- Post-insult Time to Onset of Defensive Burying Response [CMO:0001962] — Measurement of the length of time between the introduction of, or an experimental subject's first encounter with, a stimulus and commensement of the activity of defensive burying by that subject.
- Post-insult Time to Onset of Diabetes Mellitus [CMO:0001582] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of diabetes mellitus, a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance and resulting in hyperglycemia due to decreased glucose tolerance.
- Post-insult Time to Onset of Experimental Arthritis [CMO:0001450] — Measurement of the length of time between introduction of a disease-producing stimulus to the observation of symptoms of experimental arthritis, a disease characterized by inflammation of one or more joints, the sites of junction or union between bones, especially those that allow motion of the bones, in which the condition is a result of the artificial induction of joint inflammation.
- Post-insult Time to Onset of Experimental Autoimmune Encephalomyelitis [CMO:0001422] — Measurement of the length of time between introduction of a disease-producing stimulus to the observation of symptoms of experimental autoimmune encephalomyelitis (EAE), an animal model of brain inflammation in which inflammation is induced through immunization of the animal with central nervous system antigens or by the passive transfer of autoreactive T cells.
- Post-insult Time to Onset of Experimental Autoimmune Neuritis [CMO:0001526] — Measurement of the length of time between introduction of a disease-producing stimulus to the observation of symptoms of experimental autoimmune neuritis (EAN), inflammation of peripheral nerves caused by an anti-self immune reaction experimentally or artificially triggered by introduction of peripheral nerve tissue or protein components in adjuvant.
- Post-insult Time to Onset of Experimental Diabetes Mellitus [CMO:0001994] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of experimental diabetes mellitus, diabetes induced experimentally by administration of various diabetogenic agents or by removal of all or part of the pancreas.
- Post-insult Time to Onset of Herpes Simplex Encephalitis [CMO:0002373] — Measurement of the length of time between introduction of the herpes simplex virus (HSV) and the observation of symptoms of HSV-induced encephalitis, an acute (or rarely chronic) inflammatory process of the brain caused by Simplexvirus infections which may be fatal.
- Post-insult Time to Onset of Leukemia [CMO:0001904] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of leukemia, any of a group of progressive, malignant diseases of the blood-forming organs, marked by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow.
- Post-insult Time to Onset of Moribundity [CMO:0001896] — Measurement of the length of time between introduction of a noxious, toxic or disease-producing stimulus to the observation of symptoms of moribundity, the state or quality of being on the verge of death or in the process of dying.
- Post-insult Time to Onset of T-cell Lymphoma [CMO:0001907] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of T-cell lymphoma. T-cell lymphoma refers to a heterogeneous group of usually malignant lymphoid neoplasms that occur as circumscribed solid tumors and that are composed of T lymphocytes. T lymphocytes are white blood cells that complete maturation in the thymus and that have various roles in the immune system, including the identification of specific foreign antigens in the body, the mediation of cellular immune responses, and the activation and deactivation of other immune cells.
- Post-insult Time to Onset of Type 1 Diabetes Mellitus [CMO:0001996] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of type 1 diabetes mellitus (T1DM). T1DM is a form of diabetes mellitus which results from the autoimmune destruction of beta cells of the pancreatic islets of Langerhans.
- Post-insult Time to Onset of Type 2 Diabetes Mellitus [CMO:0001995] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of symptoms of type 2 diabetes mellitus (T2DM). T2DM is a form of diabetes often, although not universally, associated with obesity, insulin resistance, hyperlipidemia(s) and cardiovascular symptoms such as hypertension.
- Post-insult Time to Pituitary Tumor Formation [CMO:0001026] — The amount of time to the first discernible appearance of tumor in the pituitary gland following the administration of a tumor causing agent.
- Post-insult Time to Trigeminal Nerve Neurilemmoma Formation [CMO:0002019] — Measurement of the length of time between introduction of a disease-producing stimulus and the observation of trigeminal nerve neurilemmomas - tumors originating in the myelin sheath of the trigeminal nerve, either of the fifth pair of cranial nerves which function as the chief sensory nerves of the face and the motor nerves of the muscles of mastication.
- Post-treatment Survival Time from Doxorubicin-treated IgM Immunocytoma [CMO:0003866] — This is a measurement of the length of time between introduction of a doxorubicin treatment protocol for an IgM immunocytoma and the death of the subject, i.e. the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
- Post-treatment Survival Time from Drug-treated IgM Immunocytoma [CMO:0003867] — This is a measurement of the length of time between introduction of a drug treatment protocol for an IgM immunocytoma and the death of the subject, i.e. the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
- Posterior Cerebral Artery Inner Diameter [CMO:0001129] — The length of a line which crosses a transverse view of a posterior cerebral artery, passing through its center and ending on either side at the inner surface of the blood vessel wall. The posterior cerebral artery (PCA) is one of a pair of blood vessels that supply blood to the posterior aspect, i.e. the occipital lobe, of the brain.
- Potassium Chloride Response/sensitivity Measurement [CMO:0002461] — Measurement of an organism's, organ's, tissue's or cell's capacity to respond, such as by a change in activity, state or condition, to potassium chloride, the salt of the potassium cation (K+) and the chlorine/chloride anion (Cl-). Potassium chloride is used as an eletroylyte replenisher and has mild vasoconstrictive properties when applied directly to blood vessels.
- Potassium Chloride-induced Blood Vessel Contractile Force Expressed as Percent of Force at Baseline [CMO:0002460] — A calculated measurement in which the difference between the contractile force of a blood vessel in response to a specified dosage of potassium chloride and the baseline contractile force exerted by that vessel in the absence of any external stimuli, is divided by the baseline contractile force measurement and the result expressed as a percentage. Potassium chloride is the salt of the potassium cation (K+) and the chlorine/chloride anion (Cl-). It is used as an eletroylyte replenisher and has mild vasoconstrictive properties when applied directly to blood vessels.
- PP Interval [CMO:0000278] — An interval measured from the onset of the P wave in one PQRST wave complex to the onset of the P wave in the following PQRST wave complex.
- PR Interval [CMO:0000233] — Time between the beginning of the P wave to the beginning of the QRS complex, reflects the time the electrical impulse takes to travel from the sinus node through the AV node and entering the ventricles, used as an estimate of AV node function.
- Preload Recruitable Left Ventricle Stroke Work [CMO:0002888] — Preload recruitable stroke work (PRSW) is determined by the linear regression of stroke work with the end-diastolic volume. The slope of the PRSW relationship is a highly linear index of myocardial contractility that is insensitive to preload and afterload.
- Primary Cultured Cell Ribonucleic Acid Composition Measurement [CMO:0003920] — This is any measurement of the absolute or relative amount(s) of one or more of the ribonucleic acids (RNAs) found in a specified type of cell or set of cells after in vitro cell culturing for a specified length of time without the benefit of cell passage (harvesting and reseeding/splitting into multiple daughter cultures) . Cell culture refers to the growth of isolated cells from an animal or plant in a favorable artificial environment.
- Prostate Gland Dry Weight [CMO:0000848] — The weight, after desiccation, of the prostate gland. The prostate is the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen.
- Prostate Gland Morphological Measurement [CMO:0000651] — Measurement of the physical form or structure of the prostate gland, the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen.
- Prostate Gland Ribonucleic Acid Composition Measurement [CMO:0003272] —
- Prostate Gland Weight [CMO:0000847] — The weight of the prostate gland, the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen.
- Prostate Gland Wet Weight [CMO:0000652] — The weight, after removal from the body but without desiccation, of the prostate gland. The prostate is the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen.
- Prostate Lesion Measurement [CMO:0000881] — Any measurement of one or more lesion(s) in the prostate gland, the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen. A lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined.
- Prostate Tumor Incidence/prevalence Measurement [CMO:0000935] — A measurement in which the number of individuals in a study population displaying at a point in time one or more prostate tumors--that is, abnormal growth(s) of the tissue of the prostate gland, the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen, resulting from uncontrolled, progressive multiplication of cells which serve no physiological function--or developing such growths within a determined period of time, are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
- Prostate Tumor Measurement [CMO:0000902] — Measurement of an abnormal growth of tissue in the prostate gland resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
- Prostate Tumorous Lesion Area Measurement [CMO:0000886] — A measurement of the extent of a two-dimensional surface of or plane through an individual tumorous lesion in the prostate, or a measurement of the total area occupied by tumorous lesions in a cross-section of the prostate. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors and preneoplastic lesions, as well as hyperplastic lesions composed of histologically normal cells.
- Prostate Tumorous Lesion Incidence/prevalence Measurement [CMO:0000934] — A measurement in which the number of individuals in a study population that display one or more prostate tumorous lesion(s) at a point in time or develop such lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Prostate Tumorous Lesion Measurement [CMO:0000882] — Measurement of one or more prostate lesion(s) which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Prostate Tumorous Lesion Number [CMO:0000884] — The number of tumorous lesions in the prostate gland, the gland surrounding the male urethra just below the base of the bladder which secretes a fluid that constitutes a major portion of the semen. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors and preneoplastic lesions, as well as hyperplastic lesions composed of histologically normal cells.
- Prostate Tumorous Lesion Size Measurement [CMO:0000885] — Any measurement of the size of an individual tumorous lesion in the prostate, or of the amount of the prostate occupied by tumorous lesions. A tumorous lesion is one which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.
- Prothrombin Time [CMO:0000211] — Measurement of the clotting ability of fibrinogen, prothrombin, proaccelerin, proconvertin and Stuart factor, usually given in seconds to formation of clot after the addition of a tissue factor or thromboplastin.
- Proximal Forelimb Circumference [CMO:0000317] — This is the distance around one of the paired front or upper limbs of a quadruped in the segment closest to the body.
- Proximal Gut Ribonucleic Acid Composition Measurement [CMO:0003342] —
- Proximal Hind Limb Circumference [CMO:0000019] — Distance around the upper portion of the hind limb closest to the body, typically taken at the area of maximum girth.
- Proximal Tubule Albumin Uptake to Tubule Area Ratio [CMO:0003636] — A microscopic measure of the amount of albumin reabsorbed by the proximal tubule per area of proximal tubule, where a fluorescent intensity value represents the amount of albumin reabsorbed per square area of proximal tubule.
- Pulmonary Arterial Blood Pressure Measurement [CMO:0000782] — Measurement of blood pressure in the pulmonary artery.
- Pulmonary Arterial Diastolic Blood Pressure [CMO:0000528] — Blood pressure measured in the pulmonary artery during diastole, that is, during dilation or relaxation of the heart ventricles.
- Pulmonary Arterial Systolic Blood Pressure [CMO:0000529] — Blood pressure measured in the pulmonary artery during systole, that is, during contraction of the heart ventricles.
- Pulmonary Valve Ribonucleic Acid Composition Measurement [CMO:0003327] —
- Pulmonary Vascular Resistance (PVR) [CMO:0000701] — Resistance to blood flow by blood vessels in the lung.
- Pulse [CMO:0000294] — The count of the rhythmic contractions and expansions of an artery due to the surge of blood from the beat of the heart.
- Pulse Pressure [CMO:0000292] — The difference between systolic and diastolic blood pressures, i.e. the difference between the maximal arterial pressure and minimal arterial pressure during the cardiac cycle.
- Pulse Wave Velocity [CMO:0003717] — Pulse wave velocity (PWV) is a measurement of arterial stiffness that is an independent predictor of cardiovascular risk. It can be measured simply and noninvasively by measuring the carotid and femoral pulse pressures and the time delay between the two or by other methods relying on pulse-wave analysis.
- Purkinje Cell Count [CMO:0000324] — The number of Purkinje cells, neurons in the cerebellar cortex, in a specified tissue sample.
- Putamen Ribonucleic Acid Composition Measurement [CMO:0003336] —
- Pyometritis Incidence/prevalence Measurement [CMO:0002010] — Any measurement in which the number of individuals in a study population that display pyometritis at a point in time or develop pyometritis within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. Pyometritis is a suppurative inflammation of the uterus.
- Pyometritis Severity Measurement [CMO:0002008] — Any measurement of the degree to which the presentation of the pyometritis disease state, i.e. a suppurative inflammation of the uterus, causes pain or damage, or interfers with the normal functioning of an organism or any part thereof.
- Pyometritis Severity Score [CMO:0002009] — A rating, usually expressed numerically and based on the degree to which certain qualities or conditions are present, of the degree to which the presentation of the pyometritis disease state, i.e. a suppurative inflammation of the uterus, causes pain or damage, or interfers with the normal functioning of an organism or any part thereof.
Data returned: 541 terms all with first letter "P".
Data updated: Sep 01, 2024